NIH_SPENDING_CATS: Cancer;Clinical Research;Hematology;Rare Diseases;Stem Cell Research;Stem Cell Research - Nonembryonic - Human

ORG_CITY: BIRMINGHAM

ORG_NAME: UNIVERSITY OF ALABAMA AT BIRMINGHAM

ORG_STATE: AL

PHR: PROJECT NARRATIVE Current leukemia treatments although effective in achieving remission, fail to eliminate leukemia stem cells, resulting in a high rate of relapse. The proposed research aims to develop improved understanding of the mechanisms and role of altered mitochondrial metabolism in leukemia stem cell preservation and treatment resistance, and identify metabolic vulnerabilities that can be targeted to enhance elimination of leukemia stem cells and improve outcomes for leukemia patients.

PI_NAMEs: BHATIA, RAVI  (contact)

PROGRAM_OFFICER_NAME: KLAUZINSKA, MALGORZATA

PROJECT_TERMS: Bcr-Abl tyrosine kinase;Biology;Bone Marrow;Cell Death;Cell Maintenance;Cell Physiology;Cell Survival;cell transformation;Cellular Metabolic Process;Chronic Myeloid Leukemia;cofactor;Deacetylase;Deacetylation;Development;Disease;Disease remission;Drug resistance;extracellular;fatty acid oxidation;Fatty Acids;Financial Hardship;Gene Combinations;Gene Expression;Generations;Glucose;Glutamine;Glycolysis;Goals;Hematologic Neoplasms;hematopoietic stem cell quiescence;Hematopoietic stem cells;improved;improved outcome;In Vitro;in vivo;inhibitor;Knowledge;Label;leukemia;leukemia treatment;leukemic stem cell;Maintenance;Malignant Neoplasms;mesenchymal stromal cell;Metabolic;Metabolic Pathway;Metabolism;Mitochondria;mitochondrial metabolism;Mitochondrial Proteins;Natural regeneration;new therapeutic target;overexpression;oxidation;Oxidative Phosphorylation;Patients;Play;PPAR alpha;preservation;Process;Proliferating;Protein Tyrosine Kinase;Reactive Oxygen Species;Regulation;Relapse;Remission Induction;Research;Resistance;Respiration;response;restoration;Risk;Role;self-renewal;Signal Transduction;SIRT1 gene;stem cell fate;stem cell function;stem cell growth;stem cell population;Stromal Cell-Derived Factor 1;targeted treatment;therapy resistant;Toxic effect;TP53 gene;Transcription Coactivator;transcription factor;Translations;Tyrosine Kinase Inhibitor

PROJECT_TITLE: Leukemia stem cell regulation and resistance


ADMINISTERING_IC: CA

ARRA_FUNDED: N

ED_INST_TYPE: SCHOOLS OF MEDICINE

FUNDING_MECHANISM: NON-SBIR/STTR RPGS

IC_NAME: NATIONAL CANCER INSTITUTE

NIH_SPENDING_CATS: Biotechnology;Cancer;Chronic Liver Disease and Cirrhosis;Digestive Diseases;Genetics;Hepatitis;Immunotherapy;Liver Cancer;Liver Disease;Orphan Drug;Prevention;Rare Diseases;Stem Cell Research;Stem Cell Research - Nonembryonic - Non-Human

ORG_CITY: AUGUSTA

ORG_COUNTRY: UNITED STATES

ORG_DEPT: RADIATION-DIAGNOSTIC/ONCOLOGY

ORG_FIPS: US

ORG_NAME: AUGUSTA UNIVERSITY

ORG_STATE: GA

PHR: Therapeutic  exploitation  of  oncogene  addiction  has  become  a  central  aim  of  modern  cancer  therapy,  but  effective targeted therapies for aggressive cancer types including hepatocellular carcinoma (HCC) are lacking.  In  this  proposal,  a  collaborating  team  of  experts  will  investigate  whether  a  valid  approach  for  therapeutic  interventions  in  HCC  can  be  based  on  a  strategy  to  inhibit  supportive  non- oncogene  addiction  pathways,  interfering  with  tumor- promoting  metabolic  reprogramming  and  improving  the  predicted  power  of  anti- tumor  immunity  through  depletion  of  Hsf1.  This  research  will  provide  the  rationale  to  develop  novel  strategies  to  prevent, and perhaps treat, cancers, including HCC, that arise on the background of chronic hepatic injury due  to impaired liver metabolism, protein homeostasis and suppression of anti- tumor immunity.

PI_NAMEs: MIVECHI, NAHID F (contact);MOSKOFIDIS, DIMITRIOS

PROGRAM_OFFICER_NAME: ZAMISCH, MONICA

PROJECT_TERMS: Ablation;adaptive immunity;Adoptive Transfer;Affect;AFP gene;Alcohols;anti-tumor immune response;Attenuated;Automobile Driving;Bioenergetics;cancer cell;cancer initiation;Cancer Model;Cancer Patient;cancer survival;cancer therapy;cancer type;CD8-Positive T-Lymphocytes;Cells;Cellular Immunity;Cellular immunotherapy;Cessation of life;checkpoint therapy;chemotherapy;Chemotherapy and/or radiation;Chromatin;Chronic;Cirrhosis;Clinical;Clinical Trials;Collaborations;CRISPR/Cas technology;Curative Surgery;curative treatments;Developed Countries;Developing Countries;Development;Disease;effective therapy;Effector Cell;Engineering;Epidemic;Epigenetic Process;epigenetic regulation;Excision;exhaustion;Exhibits;Experimental Designs;experimental study;Fibrosis;fitness;Frequencies;Functional disorder;Funding;Generations;Genes;Genetic;genetic makeup;genetic signature;Genetic Transcription;heat shock transcription factor;Heat-Shock Response;Hepatic;Hepatitis B Virus;Hepatitis C virus;Hepatocarcinogenesis;HSF1;Human;Immune;Immunologic Surveillance;immunological intervention;Immunotherapeutic agent;Immunotherapy;Impairment;improved;Incidence;Individual;individual patient;Inflammation;Link;liquid chromatography mass spectrometry;Liver;Liver Dysfunction;liver inflammation;liver injury;liver metabolism;Liver neoplasms;long term memory;Maintenance;Malignant - descriptor;Malignant neoplasm of liver;Malignant Neoplasms;Mass Fragmentography;Mediating;Memory;Metabolic;Metabolic Diseases;Metabolic Pathway;metabolic profile;Metabolic syndrome;Metabolism;metabolomics;Methods;Modality;Modernization;Molecular;mouse model;Mus;Mutation;Neoplasm Metastasis;non-alcoholic fatty liver disease;novel;novel strategies;novel therapeutic intervention;Obesity;Obesity Epidemic;oncogene addiction;Oncogenic;Outcome;Pathogenesis;Pathogenicity;Pathway interactions;Patients;Population;pre-clinical;Prevalence;prevent;Primary carcinoma of the liver cells;progenitor;programs;protein folding;Proteome;proteostasis;Publishing;Recurrent tumor;Regulation;Research;Resistance;Risk;Risk Factors;Role;Safety;Signal Transduction;stem;stem cells;stemness;Stress;T cell response;T cell therapy;T-Lymphocyte;targeted treatment;Testing;Therapeutic;Therapeutic Effect;Therapeutic Intervention;therapeutic target;therapeutically effective;Time;translational goal;Treatment Efficacy;treatment strategy;tumor;Tumor Immunity;tumor initiation;Tumor Promotion;tumorigenesis;Vaccines;Virus Diseases;Work

PROJECT_TITLE: Role of heat shock transcription factor HSF1 in tumorigenesis

STUDY_SECTION: RTB

STUDY_SECTION_NAME: Radiation Therapeutics and Biology Study Section[RTB]


FUNDING_MECHANISM: RESEARCH CENTERS

NIH_SPENDING_CATS: Biotechnology;Cancer;Immunotherapy

ORG_CITY: PHILADELPHIA

ORG_NAME: UNIVERSITY OF PENNSYLVANIA

ORG_STATE: PA

PI_NAMEs: PEAR, WARREN S (contact)

PROJECT_TERMS: Achievement;Acute leukemia;Agonist;Animal Model;Antigen-Antibody Complex;Basic Science;bench to bedside;Biological;Biology;biomarker discovery;cancer care;cancer cell;Cancer Center;Cancer Center Support Grant;cancer immunobiology;cancer immunotherapy;cancer prevention;Cancer Science;cancer therapy;CAR T cell therapy;Caring;Catchment Area;Cell Therapy;Cells;checkpoint inhibition;chimeric antigen receptor T cells;Clinic;Clinical;clinical biomarkers;Clinical Sciences;clinical translation;Clinical Trials;Collaborations;Comprehensive Cancer Center;design;Development;Direct Costs;Doctor of Philosophy;exceptional responders;exhaustion;experience;FDA approved;forging;Foundations;Funding;Goals;Grant;Hematologic Neoplasms;Human;Immune;immune health;Immune response;Immunobiology;Immunologic Surveillance;Immunologics;Immunology;Immunotherapy;improved;In Vitro;Industry;insight;Institution;interest;International;Journals;leukocyte activation;Leukocytes;Malignant - descriptor;Malignant Neoplasms;Measures;meetings;member;Mission;Molecular;Molecular Biology;Myeloid Cells;neoplasm immunotherapy;novel;novel therapeutics;oncology program;Outcome;Pathway interactions;Patients;Pear;Pediatric Oncology;Peer Review;Pilot Projects;Population Sciences;Process;programs;Proteomics;Publications;Publishing;rational design;recruit;Research;Research Personnel;Research Project Grants;Resistance;resistance mechanism;Resource Sharing;Resources;response;Schools;Science;Solid Neoplasm;success;System;T cell differentiation;T-Lymphocyte;Therapeutic;therapy development;Time;Training Programs;Translating;Translational Research;Translations;tumor;tumor immunology;Vaccines;Work

PROJECT_TITLE: Immunobiology Program

STUDY_SECTION: NCI

STUDY_SECTION_NAME: Cancer Centers Study Section (A)[NCI-A]


NIH_SPENDING_CATS: Bioengineering;Biomedical Imaging;Cancer;Lung;Lung Cancer;Radiation Oncology

ORG_NAME: THOMAS JEFFERSON UNIVERSITY

PHR: Our project proposes to form an academic-industrial partnership to translate a novel lung function imaging modality into radiotherapy clinical care for lung cancer patients. The novel lung function imaging modality is referred to as `4DCT-ventilation,' and uses 4-Dimensional CT data along with image processing techniques to innovatively calculate lung functional maps. 4DCT-ventilation has great potential to reduce toxicity and improve outcomes for lung cancer patients undergoing radiation therapy. Our project will develop methods that will enable widespread clinical integration of this novel imaging modality.

PI_NAMEs: CASTILLO, EDWARD ;CASTILLO, RICHARD ;VINOGRADSKIY, YEVGENIY  (contact)

PROGRAM_OFFICER_NAME: KIM, BOKLYE

PROJECT_TERMS: Address;Algorithms;Anatomy;automated segmentation;Cancer Patient;Characteristics;Chest;Clinic;Clinical;clinical care;Clinical Data;clinical practice;Clinical Trials;clinically significant;Commercial grade;community center;Computer software;Data;Data Set;Development;Dose;early phase trial;Engineering;Environment;Evaluation;experience;Feasibility Studies;Four-dimensional;four-dimensional computed tomography;Generations;Heterogeneity;Image;image processing;imaging modality;imaging program;Imaging Techniques;improved;improved outcome;Individual;Industrialization;industry partner;innovation;Institution;Knowledge;Life;Lung;machine learning method;Malignant neoplasm of lung;Maps;Methods;novel;novel imaging technique;Patients;Performance;Physiological;prospective;pulmonary function;quality assurance;Quality of life;Radiation;Radiation Pneumonitis;Radiation therapy;Research;Resolution;Retrospective Studies;Seminal;side effect;software development;Software Tools;standard of care;Study models;System;Techniques;tool;Toxic effect;Translating;Treatment Side Effects;Validation;ventilation

PROJECT_TITLE: Development of a Novel Lung Function Imaging Modality for comprehensive management of lung cancer


ADMINISTERING_IC: DK

FUNDING_MECHANISM: OTHER RESEARCH-RELATED

IC_NAME: NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES

NIH_SPENDING_CATS: Diabetes;Genetics;Kidney Disease

ORG_CITY: NEW YORK

ORG_DEPT: INTERNAL MEDICINE/MEDICINE

ORG_NAME: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI

ORG_STATE: NY

PHR: Project Narrative Diabetic kidney disease (DKD) is the common cause of end-stage renal disease in the US. However current regimen provides only partial therapeutic effects and the incidence and prevalence of these diseases remains high, suggesting that the key pathogenic mechanisms driving DKD progression are not adequately inhibited by current treatments. The current proposal to study the glomerular endothelial cell injury in the diabetic kidney could help us to develop potential new therapy for DKD.

PI_NAMEs: FU, JIA  (contact)

PROGRAM_OFFICER_NAME: RANKIN, TRACY L

PROJECT_TERMS: ADGR1 gene;adhesion receptor;Adhesions;Advanced Glycosylation End Products;Affect;Albuminuria;angiogenesis;Attenuated;Automobile Driving;cell injury;Cell Physiology;Cell Separation;Cell Survival;Cells;Code;Collagen;Cyclic AMP;Cyclic AMP-Dependent Protein Kinases;Data;Development;Diabetes Mellitus;diabetic;Diabetic Nephropathy;differential expression;Disease;Disease Progression;End stage renal failure;Endothelial Cells;Endothelium;Event;Extracellular Matrix Proteins;Fibronectins;Functional disorder;G-Protein Signaling Pathway;G-Protein-Coupled Receptors;Genes;glomerular endothelium;Glucose;GPR3 gene;Heparin;Human;Immunity;In Vitro;in vivo;Incidence;Injury;Kidney;Kidney Diseases;Knock-out;Knockout Mice;Learning Skill;Ligands;Mediating;Melanoma;Mentors;Methods;Microalbuminuria;mRNA Expression;Mus;neuron development;non-diabetic;NOS3 gene;novel;novel therapeutics;Pathogenicity;Pathway interactions;Permeability;Phosphorylation;Play;podocyte;post-doctoral training;Postdoctoral Fellow;Prevalence;Principal Investigator;Process;promoter;protein expression;Proteins;Regimen;Regulation;Research Personnel;Role;shear stress;Signal Pathway;Signal Transduction;single-cell RNA sequencing;Sorting;Streptozocin;Sulfate;Techniques;Testing;Therapeutic Effect;Therapeutic Intervention;Tissues;transcriptome;transcriptome sequencing;transcriptomics;Transgenic Mice;Tumor Biology;Vascular Endothelial Growth Factors

PROJECT_TITLE: Role of GPR56 in glomerular endothelial cell injury in early diabetic kidney disease

STUDY_SECTION: DDK

STUDY_SECTION_NAME: Kidney, Urologic and Hematologic Diseases D Study Section[DDK-D]


PI_NAMEs: BERGER, SHELLEY L (contact)

PROJECT_TERMS: Abbreviations;Academy;acronyms;American;American Cancer Society;androgen independent prostate cancer;Androgen Receptor;anti-cancer research;Antineoplastic Agents;Applied Research;Area;Arts;Award;Basic Cancer Research;Basic Science;Biological;Biological Assay;Cancer Biology;cancer cell;Cancer Center;Cancer Center Support Grant;cancer initiation;Cancer Model;Catchment Area;Cells;Cellular biology;Chemoresistance;chimeric antigen receptor;Chromatin;Clear cell renal cell carcinoma;Clinic;clinical investigation;Collaborations;community engagement;Community Outreach;Conventional (Clear Cell) Renal Cell Carcinoma;Dental Schools;Detection;Diagnostic;Direct Costs;DNA Methylation;DNA Sequence;Doctor of Philosophy;doctoral student;Drosophila genus;drug sensitivity;Early Diagnosis;Early treatment;Education;Endothelial Cells;Engineering;Environment;environmental carcinogenesis;Epidermal Growth Factor Receptor;Epigenetic Process;epigenetic regulation;epithelial to mesenchymal transition;Epithelium;Eye;Faculty;Fostering;Funding;Gene Expression;genome integrity;Glioblastoma;Goals;Grant;health disparity;Heritability;High Mobility Group Proteins;High School Student;histone modification;HMGB Family Gene;IFNAR1 gene;Image;imaging program;Immune;Immune Evasion;In Vitro;in vivo Model;Inflammation;innovation;insight;Institution;interest;Leadership;Malignant Neoplasms;Mass Spectrum Analysis;Medal;medical schools;Medicine;meetings;member;Mentors;Mentorship;Mesenchymal;Metabolism;Methods;mimicry;Molecular;Molecular Biology;Mutation;novel;optogenetics;Pancreatic Ductal Adenocarcinoma;Paper;Pathway interactions;Peer Review;Pennsylvania;Philadelphia;Physicians;Play;Postdoctoral Fellow;Prevention strategy;Preventive;Process;prognostic;programs;protein B;Publications;Publishing;Radiobiology;recruit;Research;Retinoblastoma;Role;Scholars Program;school district;Schools;Science;Scientist;Signal Pathway;Signal Transduction;Societies;Stromal Cells;success;symposium;Technology;Therapeutic;tobacco carcinogenesis;Training;Transcriptional Regulation;Translating;Transposase;tumor;Tumor Biology;Tumor Escape;tumor growth;tumor initiation;tumor microenvironment;tumor progression;tumorigenesis;type I interferon receptor;undergraduate student;United States National Academy of Sciences;United States National Institutes of Health;Universities;Veterinary Medicine;Veterinary Schools;Viral;XCL1 gene

PROJECT_TITLE: Tumor Biology Program


FUNDING_MECHANISM: TRAINING, INDIVIDUAL

NIH_SPENDING_CATS: Cancer;Immunotherapy

ORG_CITY: DALLAS

ORG_DEPT: PATHOLOGY

ORG_NAME: UT SOUTHWESTERN MEDICAL CENTER

ORG_STATE: TX

PHR: Project Narrative: Solid tumors remain one of the leading causes of death in the United States because their complex microenvironment resists conventional treatment modalities. I have generated a novel IL12 prodrug that potently activates immune cells without adverse effects, allowing the administration of doses capable of eradicating solid tumors in mice. Through pharmacokinetic and mechanistic studies, I will ascertain exactly how this prodrug functions, bringing it one step closer to treating cancer in patients.

PI_NAMEs: MOON, BENJAMIN  (contact)

PROGRAM_OFFICER_NAME: ODEH, HANA M

PROJECT_TERMS: Accounting;Acidity;Adoptive Transfer;Adverse effects;Affinity;Antibodies;antitumor effect;Antitumor Response;Binding;Biodistribution;Biological Assay;Biological Markers;Blood;Body Weight;Body Weight decreased;Body Weights and Measures;C57BL/6 Mouse;cancer immunotherapy;Cause of Death;CD8-Positive T-Lymphocytes;CD8B1 gene;Cell Differentiation process;cell type;Cells;Cellular Immunity;Cessation of life;Clinical;clinical development;Clinical Trials;Combined Modality Therapy;Complex;conventional therapy;cytokine;Data;Development;Dose;Drug Design;Drug Kinetics;Effector Cell;Enzymes;Exposure to;flexibility;Future;genetic signature;Goals;Histology;Homeostasis;Human;Hypoxia;IFNGR1 gene;Immune;immune checkpoint;Immune checkpoint inhibitor;Immune response;Immunotherapeutic agent;Immunotherapy;Impairment;improved;in vivo;insight;Interferon Type II;Interleukin-12;interleukin-12 receptor;Kinetics;Lymphoid Cell;Malignant Neoplasms;MC38;Measures;Mediating;MMP14 gene;Modality;Modeling;Molecular;Molecular Conformation;Monitor;Mus;Natural Killer Cells;Near-infrared optical imaging;Neoplasm Metastasis;neoplastic cell;novel;novel therapeutics;overexpression;Patients;Pharmaceutical Preparations;Play;Pre-Clinical Model;preclinical study;preclinical trial;prevent;Prodrugs;Production;Prognostic Marker;Property;Refractory;response;Role;Schedule;Serum;Signal Pathway;Signal Transduction;single-cell RNA sequencing;Site;Solid Neoplasm;subcutaneous;success;Supporting Cell;synergism;T-Cell Activation;T-Lymphocyte;Testing;Tissue Sample;Toxic effect;tumor;tumor eradication;Tumor Immunity;tumor microenvironment;Tumor-infiltrating immune cells;United States

PROJECT_TITLE: Development of a tumor-activated IL12 prodrug to treat solid tumors


ADMINISTERING_IC: DA

IC_NAME: NATIONAL INSTITUTE ON DRUG ABUSE

NIH_SPENDING_CATS: Behavioral and Social Science;Cannabidiol Research;Cannabinoid Research;Chronic Pain;Clinical Research;Complementary and Integrative Health;Drug Abuse (NIDA only);Natural Products;Opioids;Pain Research;Physical Injury - Accidents and Adverse Effects;Substance Misuse;Therapeutic Cannabinoid Research

ORG_CITY: Aurora

ORG_DEPT: PSYCHIATRY

ORG_NAME: UNIVERSITY OF COLORADO DENVER

ORG_STATE: CO

PHR: Research Narrative The United States is facing an opiate epidemic that is spiraling out of control, with a recent CDC report finding that drug overdoses kill one and a half times more people annually than motor vehicle accidents. The proposed research of the effects of cannabis on opiate use is timely and would address a glaring gap in the knowledge base in ways that could potentially have an important public health impact. The proposed patient-centered, observational, adaptive intervention design will compare three broad classes of cannabis products: a THC only product, a product that has a 1:1 THC to CBD ratio, and a CBD only product over the course of 12 weeks in a sample of individuals who want to reduce their opiate use and plan to use cannabis to do so.

PI_NAMEs: HUTCHISON, KENT E. (contact)

PROGRAM_OFFICER_NAME: MOLLICK, JESSICA ANN

PROJECT_TERMS: Acute;adaptive intervention;Address;Automobile Driving;Biological Assay;Blood;Blood specimen;Cannabidiol;Cannabinoids;Cannabis;Cannabis retail;cannabis self-administration;chronic pain;chronic pain management;chronic painful condition;Climate;Clinical;Clinical Research;Cognitive;cognitive function;Colorado;comparative effectiveness study;Complex;Country;craving;Data;Dose;Effectiveness;effectiveness evaluation;Epidemic;experience;Future;Government;Health Personnel;High Prevalence;Individual;innovation;Institution;knowledge base;Laboratories;Laws;Legal;Light;marijuana use;marijuana user;Marketing;Measures;Mediating;Medical;Medical Marijuana;Methodology;Motivation;novel strategies;Observational Study;Opioid;opioid overdose;opioid use;opioid withdrawal;Oral Administration;Outcome;Overdose;overdose death;Pain;Pain management;pain outcome;pain patient;patient oriented;patient registry;Patient Self-Report;Patients;Persons;Pharmaceutical Preparations;Pharmacology;Plants;Play;Policy Maker;Population;Prospective Studies;Provider;Public Health;Publishing;Randomized, Controlled Trials;Recreation;Reporting;Research;response;Role;Safety;Sampling;Sativex;Scientist;secondary outcome;selective attention;side effect;Surveys;systematic review;Testing;Tetrahydrocannabinol;therapy design;Time;United States;United States National Academy of Sciences;vehicular accident;verbal;virtual;Withdrawal;Work

PROJECT_TITLE: Novel Approaches to Opiate Use Reduction

STUDY_SECTION: ARM

STUDY_SECTION_NAME: Addiction Risks and Mechanisms Study Section[ARM]


NIH_SPENDING_CATS: Biomedical Imaging;Breast Cancer;Cancer;Genetics;Precision Medicine;Prevention;Women's Health Research

PI_NAMEs: DEMICHELE, ANGELA  (contact)

PROJECT_TERMS: Accreditation;Address;Aftercare;anti-cancer research;Autophagocytosis;Award;Basic Science;Biological;Biological Markers;Biological Specimen Banks;Biology;brca gene;Breast;Breast Cancer Cell;Breast Cancer Detection;breast cancer diagnosis;Breast Cancer Treatment;Cancer Biology;Cancer Burden;Cancer Center;Cancer Center Support Grant;cancer diagnosis;Cancer Etiology;cancer prevention;Cancer Research Project;Cancer Science;Caring;Catchment Area;CDK4 gene;Cell Cycle Progression;Cell Cycle Regulation;Cell Survival;Cessation of life;chimeric antigen receptor T cells;circulating biomarkers;Clinical;clinical biomarkers;Clinical Research;clinical translation;Clinical Trials;Collaborations;combinatorial;County;design;Detection;Development;Diagnosis;Direct Costs;Disease;DNA Damage;Faculty;Fostering;Foundations;Funding;Genes;Genetic;Genetic Predisposition to Disease;genetic testing;genome integrity;Genomics;Goals;Grant;Image;imaging approach;imaging modality;imaging probe;immune activation;Immune response;immunogenicity;Immunology;Immunotherapy;improved;individualized medicine;Inherited;inhibitor;innovation;Institution;Interferons;International;Intervention Trial;Ionizing radiation;Knowledge;Laboratories;Magnetic Resonance Imaging;Malignant Breast Neoplasm;Malignant Neoplasms;member;Modeling;Modernization;Molecular;Monitor;mortality;mouse model;Multicenter Trials;multidisciplinary;mutant;Nature;Needles;Neoadjuvant Therapy;new technology;new therapeutic target;novel;novel strategies;novel therapeutics;Oncogenic;Outcome;Paper;PARP inhibition;Peer Review;Penetrance;personalized screening;Population;Pre-Clinical Model;Prediction of Response to Therapy;predictive test;prevent;Prevention;Productivity;programs;Publishing;Radiation;radiomics;radiotracer;recruit;Recurrence;Research;Research Personnel;Residual Neoplasm;response;response biomarker;Risk;Risk Adjustment;Role;Schools;screening;Signal Transduction;skills;Sorbus;success;surveillance strategy;survivorship;Technology;Testing;tomosynthesis;Translating;Translations;treatment and outcome;treatment response;treatment strategy;tumor;Universities;Woman

PROJECT_TITLE: Breast Cancer Program


NIH_SPENDING_CATS: Breast Cancer;Cancer;Cancer Genomics;Clinical Research;Genetics;Human Genome;Women's Health Research

ORG_CITY: STANFORD

ORG_NAME: STANFORD UNIVERSITY

ORG_STATE: CA

PHR: PROJECT NARRATIVE Triple-negative breast cancer (TNBC) is a common, high-mortality disease, with no generally effective therapies. Immature cancer cells are strongly implicated in therapy failure but are challenging to identify. New analytical tools will allow us to determine the molecular diversity and tumorigenic potential of immature cancer cells in TNBC, thereby laying a foundation for the development of new therapies to improve TNBC outcomes.

PI_NAMEs: NEWMAN, AARON M (contact)

PROGRAM_OFFICER_NAME: YASSIN, RIHAB R

PROJECT_TERMS: 3-Dimensional;Address;Affect;African American;analytical method;analytical tool;Automobile Driving;Bioinformatics;Biological Assay;Breast;Breast Cancer Patient;Breast Cancer Treatment;cancer cell;Cancer Detection;cancer subtypes;Cell Differentiation process;Cells;chemotherapy;Clinical;cohort;cytotoxic;Data;Data Set;Development;Disease;drug development;Drug resistance;Drug Targeting;effective therapy;exome sequencing;Foundations;Gene Expression Profile;Genes;Genetic Markers;Growth;Heterogeneity;Human;human tissue;Immunotherapy;improved;in silico;innovation;Knowledge;Link;Malignant Breast Neoplasm;Malignant Neoplasms;Mammary Neoplasms;Methods;Modeling;Molecular;mortality;mutant;new therapeutic target;Normal tissue morphology;novel therapeutics;Organoids;Outcome;PARP inhibition;Patient Selection;Patients;Population;programmed cell death ligand 1;programs;Publishing;Race;relapse patients;Science;single-cell RNA sequencing;Specimen;stem cell biology;Surface;Surgical Oncology;therapy resistant;transcriptome;transcriptomics;Treatment Failure;triple-negative invasive breast carcinoma;tumor;tumor growth;tumor heterogeneity;tumorigenesis;tumorigenic;Tumorigenicity;United States;Validation

PROJECT_TITLE: Delineating developmental programs driving tumorigenesis in triple-negative breast cancer

STUDY_SECTION: CG

STUDY_SECTION_NAME: Cancer Genetics Study Section[CG]


NIH_SPENDING_CATS: Breast Cancer;Cancer;Cardiovascular;Heart Disease;Women's Health Research

ORG_CITY: STONY BROOK

ORG_NAME: STATE UNIVERSITY NEW YORK STONY BROOK

PHR: Although a mainstay for treatment of many cancers, the clinical utility of Doxorubicin (Dox) is severely limited by cardiotoxicity and there is a critical need for new therapies to mitigate these adverse effects but without interfering its efficacy against cancer. The proposed research will establish the sphingolipid enzyme nSMase2 as a mediator of Dox-induced cardiotoxicity through effects on cardiomyocyte cell death and cardiac fibrosis, and in proof-of- principle studies will demonstrate that nSMase2 inhibitors reduce cardiotoxic effects of Dox but without impacting its anti-cancer activity. Collectively, these studies will advance our basic understanding of the pathogenesis of Dox-induced cardiotoxicity and will establish nSMase2 as a novel and viable druggable target for cardioprotection.

PI_NAMEs: CLARKE, CHRISTOPHER JAMES (contact)

PROGRAM_OFFICER_NAME: CHEN, WEIWEI

PROJECT_TERMS: Adverse effects;Anthracycline;anti-cancer;anticancer activity;antitumor effect;Apoptosis;Binding;biological adaptation to stress;Biological Markers;Breast Cancer Model;cancer survival;cancer therapy;Cardiac;Cardiac Myocytes;cardioprotection;Cardiotonic Agents;Cardiotoxicity;Cardiovascular system;Cell Death;Cells;cellular targeting;Ceramides;Cessation of life;chemotherapy;Chronic;Clinical;clinical efficacy;coronary fibrosis;Data;design;Development;Dexrazoxane;DNA Damage;Doxorubicin;druggable target;early onset;Enzymes;Exposure to;FDA approved;Generations;Goals;Heart;heart damage;Heart Injuries;Image;improved;In Vitro;in vivo;Induced Cardiomyocytes;inhibitor;insight;interest;Intervention;Laboratories;loss of function;Malignant Breast Neoplasm;Malignant Neoplasms;Mediating;Mediator;Metabolism;Myocardial dysfunction;Neoplasm Metastasis;new therapeutic target;novel;novel therapeutics;Oxidative Stress;Pathogenesis;Pathology;Pathway interactions;Patients;Pharmaceutical Preparations;pharmacologic;Prevention;promoter;Publishing;Regulation;Research;response;Role;side effect;Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization;Sphingolipids;Sphingomyelinase;Survival Rate;Testing;Therapeutic;Tissues;Topoisomerase;Toxic effect;TP53 gene;translational potential;Treatment Efficacy;treatment response;Treatment-related toxicity;tumor;tumor growth;Work;Xenograft Model

PROJECT_TITLE: Neutral sphingomyelinase-2 as a mediator of Doxorubicin-induced cardiotoxicity

STUDY_SECTION: MIM

STUDY_SECTION_NAME: Myocardial Ischemia and Metabolism Study Section[MIM]


ADMINISTERING_IC: MH

IC_NAME: NATIONAL INSTITUTE OF MENTAL HEALTH

NIH_SPENDING_CATS: Autism;Brain Disorders;Genetics;Intellectual and Developmental Disabilities (IDD);Mental Health;Neurosciences

ORG_NAME: NEW YORK UNIVERSITY SCHOOL OF MEDICINE

PHR: PROJECT NARRATIVE Synaptic strength must be regulated in the face of changing levels of input in order to ensure that neurons are able to maintain their output firing within reasonable limits. Homeostatic regulation of action potential duration and synaptic efficacy works in conjunction with acutely induced Hebbian plasticity to maintain network stability and information flow. This project will study the features and mechanisms of adaptation to chronic disuse aiming to advance our understanding of how cells remodel themselves, and shed light on abnormal responses in disease states, including autism spectrum disorders.

PI_NAMEs: TSIEN, RICHARD W (contact)

PROGRAM_OFFICER_NAME: DRISCOLL, JAMIE DANIELLE

PROJECT_TERMS: Action Potentials;Acute;Affect;Agreement;Alternative Splicing;AMPA Receptors;Animal Model;Animals;Area;Attention;autism spectrum disorder;Behavioral;Biochemical;Biological;Biological Assay;Brain;Brain Diseases;Brain-Derived Neurotrophic Factor;Calcium;calmodulin-dependent protein kinase II;CDK5 gene;Cell Nucleus;Cells;Chronic;Clinical;Congenital failure of fusion;Consensus;Data;Defect;Dendritic Spines;Development;Disease;Disinhibition;Dissociation;Electrophysiology (science);Event;Failure;Feedback;Frequencies;Generations;Genes;Genetic;Genetic study;Glutamate Receptor;Heart;Hippocampus;Homeostasis;Hour;Image;in vivo;Individual;Information Protection;Intervention;Investigation;large-conductance calcium-activated potassium channels;Mediating;Messenger RNA;Modification;Molecular;Molecular Conformation;Motivation;mouse model;mRNA Precursor;Mutation;Neurons;neuropsychiatric disorder;neurotransmission;neurotransmitter release;novel;Optics;Output;Pathogenicity;Pattern;Permeability;Phosphotransferases;Physiological;Play;postsynaptic;Potassium;Potassium Channel;preservation;presynaptic;Presynaptic Terminals;prevent;Progress Reports;Property;Proteins;Recurrence;Regulation;response;RNA Splicing;Role;Schizophrenia;Sensory Deprivation;Signal Pathway;Signal Transduction;Signaling Protein;Slice;Sodium;Speed;Stroke;Synapses;synaptic function;System;Testing;Tetrodotoxin;Time;Timothy syndrome;transmission process;Variant;Visualization;voltage;Weight;Weight Gain;Work

PROJECT_TITLE: Neuronal Adaptation and Plasticity after Chronic Disuse

STUDY_SECTION: SYN

STUDY_SECTION_NAME: Synapses, Cytoskeleton and Trafficking Study Section[SYN]


NIH_SPENDING_CATS: Behavioral and Social Science;Cancer;Patient Safety;Prostate Cancer;Urologic Diseases

ORG_CITY: BOSTON

ORG_NAME: MASSACHUSETTS GENERAL HOSPITAL

ORG_STATE: MA

PHR: PROJECT NARRATIVE This study will assess the effects of physician dispensing of oral specialty drugs (i.e., dispensing of medications directly to patients by the physician) for advanced prostate cancer on utilization, financial consequences, and safety. Results from this study will have real-world implications for men with advanced prostate cancer, who are intent on getting the highest quality cancer care while avoiding financial consequences and toxicity associated with these medications.

PI_NAMEs: HOLLENBECK, BRENT K. (contact);SHAHINIAN, VAHAKN B

PROGRAM_OFFICER_NAME: DAVIDOFF, AMY

PROJECT_TERMS: abiraterone;Adherence;Adoption;advanced prostate cancer;Adverse drug effect;Adverse event;Authorization documentation;Behavior;black men;cancer care;Cancer Etiology;Cessation of life;chemotherapy;Classification;Coping Behavior;Data;Death Rate;Development;Disease;Drug Costs;Drug Targeting;Eligibility Determination;enzalutamide;Familiarity;Financial Hardship;financial incentive;Financial Support;Fostering;Heterogeneity;Home;Improve Access;improved;Incentives;interest;Malignant neoplasm of prostate;Measures;Medical;Medical Oncologist;Medical Oncology;medical specialties;Medicare;medication compliance;men;Modeling;Oral;Outcome;patient safety;Patients;Pharmaceutical Preparations;Pharmacy facility;Phase;Physicians;point of care;Population;Prednisone;Price;Recommendation;Risk;Safety;Secure;System;targeted treatment;therapy duration;Time;Toxic effect;trend;Underrepresented Populations;Uninsured Medical Expense;Urologist;Urology;Work

PROJECT_TITLE: Physician dispensing of oral specialty drugs for advanced prostate cancer and its implications for patients

STUDY_SECTION: ODHS

STUDY_SECTION_NAME: Organization and Delivery of Health Services Study Section[ODHS]


NIH_SPENDING_CATS: Biotechnology;Cancer;Immunotherapy;Orphan Drug;Precision Medicine;Rare Diseases

PI_NAMEs: HAAS, NAOMI B (contact)

PROJECT_TERMS: Acceleration;Achievement;Address;Adult;American College of Radiology Imaging Network;anti-PD-1;anti-PD-L1 antibodies;anti-PD1 therapy;Antineoplastic Agents;Autophagocytosis;Basic Science;biobank;Biological;Biological Assay;Biological Markers;Biotechnology;Cancer Biology;Cancer Burden;cancer cell;Cancer Center;Cancer Center Support Grant;cancer therapy;Catchment Area;Cellular Metabolic Process;chimeric antigen receptor;chimeric antigen receptor T cells;circulating DNA;clinical practice;Clinical Research;Clinical Trials;Collaborations;community engagement;Community Outreach;Data;Direct Costs;Disease;DNA Damage;DNA Repair;drug development;Eastern Cooperative Oncology Group;Ensure;Epigenetic Process;experience;Focus Groups;Funding;Goals;Grant;Hematologic Neoplasms;Immune response;Immunology;Immunotherapy;improved;Industry;inhibitor therapy;innovation;insight;Institution;Intervention;Intervention Trial;investigator-initiated trial;Lead;Leadership;liquid biopsy;Liquid substance;Malignant Breast Neoplasm;Malignant Childhood Neoplasm;Malignant neoplasm of lung;Malignant neoplasm of ovary;Malignant neoplasm of pancreas;Malignant neoplasm of prostate;Malignant Neoplasms;Melanoma;member;Modernization;Molecular Analysis;Monoclonal Antibodies;multidisciplinary;novel;novel therapeutics;Oncogenes;Oncology;oncology program;operation;Patient Care;Patient Monitoring;Patients;PD-1/PD-L1;Pediatric Oncology;Peer Review;Pharmacodynamics;Phase;Phase I Clinical Trials;phase I trial;phase II trial;Phase III Clinical Trials;phase III trial;Play;Poly(ADP-ribose) Polymerase Inhibitor;Positioning Attribute;precision medicine;Program Research Project Grants;programs;Publications;recruit;Research;Research Design;Research Personnel;Research Project Grants;Resistance;Resource Sharing;response biomarker;Role;Safety;Schools;Scientific Advances and Accomplishments;Scientist;Series;Serious Adverse Event;Signal Transduction;Solid Neoplasm;Structure;targeted treatment;Testing;Therapeutic;Therapeutic Research;TNFRSF5 gene;Translating;Translational Research;translational scientist;trial design;tumor;tumor metabolism;Vision;Work

PROJECT_TITLE: Cancer Therapeutics Program


ADMINISTERING_IC: GM

IC_NAME: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

ORG_CITY: RICHMOND

ORG_DEPT: GENETICS

ORG_NAME: VIRGINIA COMMONWEALTH UNIVERSITY

ORG_STATE: VA

PHR: Narrative Biomedical research drives the future of medicine, as new discoveries provide understanding of and treatments for disease. There are clear disparities in the number of underrepresented individuals who become biomedical researchers. Virginia Commonwealth University Postbaccalaureate Research Education Program (VCU PREP) will continue its successful program to prepare underrepresented scholars for highly competitive doctoral programs, and for research careers in the biomedical sciences.

PI_NAMEs: MARTIN, REBECCA KELLEY;SHIANG, RITA  (contact)

PROGRAM_OFFICER_NAME: AKACEM, LAMEESE DANA

PROJECT_TERMS: academic program;Academic Training;Admission activity;Area;Behavioral Sciences;Biological Sciences;Biology;Biomedical Research;career;Critical Thinking;Critiques;Data;Department chair;Development;Development Plans;Disease;Disparity;Doctor of Philosophy;doctoral student;education research;Educational workshop;Electronic Mail;Enrollment;Evaluation;experience;Faculty;faculty mentor;follow-up;Funding;Future;Goals;graduate school;Hispanic Americans;improved;Individual;Institution;interest;Interview;Intramural Research;Journals;LinkedIn;Literature;Manuscripts;Measurable;Medicine;meetings;member;Mentors;Mexican Americans;minority student;Minority-Serving Institution;National Institute of General Medical Sciences;Native Americans;oral communication;Outcome;outreach;Peer Review;Positioning Attribute;Postbaccalaureate;Preparation;program dissemination;programs;Publications;Publishing;Qualifying;Records;recruit;Reporting;Reproducibility;Research;Research Personnel;Research Proposals;responsible research conduct;Scholars Program;Science;Series;skills;Societies;Students;Study Skills;success;summer research;symposium;System;Teacher Professional Development;Training;Training Programs;undergraduate student;Universities;Update;Virginia;Visit;web site;Writing

STUDY_SECTION: TWD

STUDY_SECTION_NAME: Training and Workforce Development Study Section - C[TWD-C]


ADMINISTERING_IC: AA

IC_NAME: NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM

NIH_SPENDING_CATS: Alcoholism, Alcohol Use and Health;Basic Behavioral and Social Science;Behavioral and Social Science;Brain Disorders;Mental Health;Neurosciences;Substance Misuse

ORG_CITY: MINNEAPOLIS

ORG_DEPT: PHARMACOLOGY

ORG_NAME: UNIVERSITY OF MINNESOTA

ORG_STATE: MN

PHR: PROJECT NARRATIVE Repeated cycles of alcohol intoxication and withdrawal foster adaptations in brain regions that regulate mood, learning, and goal-directed behavior. This project centers on a previously undescribed alcohol-induced adaptation in the amygdala that involves a molecular target implicated in anxiety and learning. By investigating the mechanisms underlying this adaptation and its impact on circuit function and behavior, we will gain a better understanding of processes that drive alcohol withdrawal-related behavior and may identify new targets for therapeutic intervention designed to treat alcohol use disorder.

PI_NAMEs: WICKMAN, KEVIN D (contact)

PROGRAM_OFFICER_NAME: CUI, CHANGHAI

PROJECT_TERMS: Ablation;Abstinence;Adaptive Behaviors;addiction;Alcohol consumption;alcohol exposure;alcohol use disorder;Alcohol withdrawal syndrome;Alcoholic Intoxication;Alcohols;Amygdaloid structure;Anxiety;anxiety-related behavior;Association Learning;Behavior;Behavioral;Brain region;Clinical Data;Cocaine;Cognitive deficits;Collaborations;craving;Custom;Data;Development;disability;drug seeking behavior;Electrophysiology (science);Ethanol;experience;Fostering;Fright;Genetic Enhancement;Genetic Suppression;GIRK3 subunit, G protein-coupled inwardly-rectifying potassium channel;Glutamates;Goals;GTP-Binding Proteins;hippocampal pyramidal neuron;Immunoelectron Microscopy;Individual;Inhalation;Injections;insight;interdisciplinary approach;interest;Intervention;Intoxication;inward rectifier potassium channel;Knockout Mice;Lateral;Learning;Link;Literature;Measures;Medial;Mediating;Modeling;Molecular;Molecular Target;Moods;Mus;National Institute on Alcohol Abuse and Alcoholism;negative affect;neuroadaptation;Neurons;neurophysiology;Neurosciences;neurotransmission;new therapeutic target;optogenetics;pharmacologic;Play;pre-clinical;Predisposition;preventable death;Process;Publishing;receptor;Relapse;Research;Research Personnel;Rewards;Role;Signal Transduction;Source;targeted treatment;Techniques;Testing;Therapeutic Intervention;therapy design;tool;vapor;Viral;virus genetics;Withdrawal;Work

PROJECT_TITLE: Alcohol-related suppression of GIRK channel activity in the basal amygdala: a link to plasticity of glutamatergic neurotransmission and withdrawal-associated behavior?

STUDY_SECTION: NAL

STUDY_SECTION_NAME: Neurotoxicology and Alcohol Study Section[NAL]


ADMINISTERING_IC: HL

ED_INST_TYPE: UNIVERSITY-WIDE

IC_NAME: NATIONAL HEART, LUNG, AND BLOOD INSTITUTE

NIH_SPENDING_CATS: Cardiovascular;Clinical Research;Congenital Heart Disease;Congenital Structural Anomalies;Genetics;Heart Disease;Human Genome;Pediatric;Primary Immunodeficiencies;Rare Diseases

ORG_CITY: BRONX

ORG_NAME: ALBERT EINSTEIN COLLEGE OF MEDICINE

PHR: NARRATIVE This project will take human and animal model genetic approaches to understand the basis of phenotypic variability of congenital heart disease among 22q11.2 deletion syndrome patients. We will analyze whole genome sequence from subjects with 22q11.2 deletion syndrome with/out congenital heart defects and validate discoveries in mouse and zebrafish models. Some of the genes studied may also be risk factors for sporadic congenital heart disease in the general population.

PI_NAMEs: MORROW, BERNICE E (contact)

PROGRAM_OFFICER_NAME: LI, HUIQING

PROJECT_TERMS: 22q11;22q11.2;Affect;Animal Model;Aorta;aortic arch;ATAC-seq;Award;Biological;Biological Models;Biology;Birth;Cardiac;cell motility;Cells;ChIP-seq;Chromatin;Chromosomes;Code;Collaborations;Congenital Abnormality;congenital heart abnormality;Congenital Heart Defects;Contracts;cost;CRISPR/Cas technology;Data;Defect;Development;Diagnostic;differential expression;DiGeorge Syndrome;Disease;DNA;Elements;Embryo;Embryonic Development;Etiology;experimental study;functional genomics;Future;gene discovery;Gene Expression Profile;General Population;Genes;Genetic;genetic approach;genetic architecture;genetic association;Genetic study;Genome;genomic data;Goals;Hand;Heart;Human;Human Genetics;human model;Immunofluorescence Immunologic;improved;In Situ Hybridization;Incidence;Individual;insertion/deletion mutation;interest;Investigation;Joints;Left;Light;Live Birth;loss of function;Lung;malformation;Maps;model organism;Modeling;Molecular;mouse model;Mus;mutant;Mutant Strains Mice;Neural Crest;novel;Nucleotides;Operative Surgical Procedures;Outcome;Pathogenesis;Patients;Persistent Truncus Arteriosus;Pharyngeal Apparatus;Phenotype;phenotypic data;programs;Quality Control;Quantitative Reverse Transcriptase PCR;Regulator Genes;Risk;Risk Factors;risk prediction;Sampling;Side;Single Nucleotide Polymorphism;single-cell RNA sequencing;spatiotemporal;stem cells;Study models;Syndrome;System;Testing;Tetralogy of Fallot;transcription factor;transcriptomics;United States National Institutes of Health;Untranslated RNA;Validation;validation studies;Variant;Ventricular Septal Defects;Weight;whole genome;Zebrafish

PROJECT_TITLE: Genetic modifiers of congenital heart disease in 22q11.2 deletion syndrome

STUDY_SECTION: GHD

STUDY_SECTION_NAME: Genetics of Health and Disease Study Section[GHD]


NIH_SPENDING_CATS: Basic Behavioral and Social Science;Behavioral and Social Science;Childhood Obesity;Clinical Research;Mental Health;Neurosciences;Nutrition;Obesity;Pediatric;Prevention

ORG_CITY: Los Angeles

ORG_DEPT: PUBLIC HEALTH & PREV MEDICINE

ORG_NAME: UNIVERSITY OF SOUTHERN CALIFORNIA

PHR: PROJECT NARRATIVE/RELEVANCE Obesity is associated with increased risk for chronic diseases and mortality. Diet and eating behaviors are important modifiable behaviors that can reduce obesity and help maintain a healthy weight. The proposed project will study the association between cognition, specifically inhibitory control, and eating and dietary intake behaviors in a sample of adolescents with the goal of elucidating inhibitory control as an important factor related to eating and dietary intake behaviors in adolescents.

PI_NAMEs: MASON, TYLER  (contact)

PROGRAM_OFFICER_NAME: SASLOWSKY, DAVID E

PROJECT_TERMS: Adaptive Behaviors;Address;Adolescence;Adolescent;Adolescent obesity;Adult;Affect;Area;Behavior;Behavioral;Binge Eating;biobehavior;blood oxygen level dependent;Body mass index;Brain;brain based;career;Cellular Phone;Child;Chronic Disease;Clinical;Cognition;Cognitive;cognitive control;contextual factors;critical developmental period;Data;Decision Making;Development;Diet;dietary;Dietary intake;Early Intervention;Eating;Eating Behavior;Ecological momentary assessment;Failure;Food;food consumption;Foundations;fruits and vegetables;Functional Magnetic Resonance Imaging;Goals;Habits;Health;Health behavior;health care service utilization;Healthy Eating;healthy weight;high body mass index;Hour;Image;Individual Differences;Intake;Interdisciplinary Study;Interruption;K-Series Research Career Programs;Knowledge;Laboratories;Life;life span;Link;Literature;Maps;Measures;Methodology;Methods;modifiable behavior;mortality;negative affect;neural;Neurobiology;neuroimaging;Neurosciences;Obesity;obesity prevention;obesity treatment;Overweight;Parents;Pathway interactions;Patient Self-Report;Pattern;peer;Persons;Prevention;Prevention program;Prevention Research;preventive intervention;Process;programs;Public Health;Quality of life;Research;Research Design;Research Personnel;Research Project Grants;response;Risk;Sampling;saturated fat;Social Environment;Stress;sugar;theories;Time;Training;Translating;Unhealthy Diet

PROJECT_TITLE: Biobehavioral Effects of Inhibitory Control on Eating and Diet Behaviors Among Adolescents

STUDY_SECTION_NAME: Digestive Diseases and Nutrition C Study Section[DDK-C]


ADMINISTERING_IC: NS

IC_NAME: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

NIH_SPENDING_CATS: Amyotrophic Lateral Sclerosis (ALS);Brain Disorders;Neurodegenerative;Neurosciences;Rare Diseases

ORG_DEPT: NEUROSCIENCES

ORG_NAME: TUFTS UNIVERSITY BOSTON

PHR: Narrative  Amyotrophic Lateral Sclerosis (ALS) is a typical progressive neurodegenerative disease in which a majority of upper and lower motor neurons (UMNs and LMNs) are degenerated. In ALS, dysfunctions of MN axons have been widely observed, which often precede motor neuronal soma and axon degeneration. This project will investigate novel roles of astroglial exosomes in promoting axon growth, functions, and (motor) neuron survival especially in ALS models. Results from this project will reveal a new astroglial exosomal HepaCAM-mediated pathway and downstream signaling in modulating (motor) neuron axon growth and survival. It will also provide important knowledge about the loss-of-functional effect of astroglial exosomes in ALS. These studies will significantly advance our understanding of the astroglial dysfunction in ALS and help develop new astroglia-based neuroprotective strategies.

PI_NAMEs: YANG, YONGJIE  (contact)

PROGRAM_OFFICER_NAME: GUBITZ, AMELIE

PROJECT_TERMS: Adhesions;Affect;ALS patients;Amyotrophic Lateral Sclerosis;Animal Model;Astrocytes;Autopsy;Axon;axon growth;axon guidance;axonal degeneration;Biochemical;Brain;Cell Adhesion Molecules;Cell Line;cell type;Central Nervous System;Conditioned Culture Media;cytokine;Data;Dendritic Spines;Diameter;Disease;Endosomes;Energy Supply;excitotoxicity;exosome;extracellular vesicles;Focal Adhesion Kinase 1;Functional disorder;functional loss;Growth Cones;Health;Human;Image;induced pluripotent stem cell;Inflammatory;Infusion procedures;Injections;Integrins;Knowledge;loss of function;Mediating;Methods;Microfluidics;Modeling;Molecular;Molecular Biology;Molecular Motors;Molecular Sieve Chromatography;Morphology;Motor;motor disorder;motor impairment;Motor Neurons;mouse genetics;Multivesicular Body;Mus;mutant;Mutation;N-Cadherin;Neurodegenerative Disorders;Neuroglia;neuronal cell body;neuronal survival;Neurons;neuroprotection;neurotransmission;novel;Outcome;Pathogenesis;Pathology;Pathway interactions;Peripheral Nerves;pharmacologic;Phosphotransferases;Play;Property;protective effect;Protein Secretion;protein transport;Proteomics;Reporter;Role;selective expression;Signal Transduction;Spinal;Spinal Cord;Structure;superoxide dismutase 1;synaptogenesis;Testing;Tissue Model;Transgenic Organisms;Ultracentrifugation;Virus

PROJECT_TITLE: Dysfunctional Astroglial Exosome to (motor) Neuron Axon Signaling in ALS

STUDY_SECTION: CMBG

STUDY_SECTION_NAME: Cellular and Molecular Biology of Glia Study Section[CMBG]


NIH_SPENDING_CATS: Biotechnology;Cancer;Childhood Leukemia;Hematology;Immunotherapy;Lymphatic Research;Lymphoma;Orphan Drug;Pediatric;Pediatric Cancer;Rare Diseases;Stem Cell Research;Stem Cell Research - Nonembryonic - Human;Transplantation

PI_NAMEs: STADTMAUER, EDWARD A (contact)

PROJECT_TERMS: Acute Myelocytic Leukemia;Adult;Area;B-Cell Lymphomas;B-Cell NonHodgkins Lymphoma;Basic Science;Biochemical Process;Bioinformatics;Biometry;Blood;Bone Marrow Transplantation;Cancer Center Support Grant;Cancer Control;CAR T cell therapy;Caring;Catchment Area;CD19 gene;Cell Physiology;Cell Separation;Cell Therapy;Cell Transplantation;chimeric antigen receptor T cells;Clinic;Clinical;Clinical Investigator;Clinical Research;Clinical Trials;Clustered Regularly Interspaced Short Palindromic Repeats;Collaborations;Communication;Communities;comparative;design;Enrollment;Epigenetic Process;FDA approved;first-in-human;Flow Cytometry;FLT3 gene;FLT3 inhibitor;Fostering;Funding;Genetic Processes;Genetic Transcription;Genomics;Goals;graft vs host disease;Grant;Group Meetings;Hematologic Neoplasms;Hematopoiesis;Hematopoietic Neoplasms;Hematopoietic stem cells;Human;Immunobiology;Immunology;Immunotherapy;innovation;Institution;International;Intervention;Intervention Trial;Investigation;investigator-initiated trial;Investments;Journals;Laboratories;Leadership;leukemia;lymphoid neoplasm;Lymphoma;Malignant - descriptor;Malignant lymphoid neoplasm;Malignant Neoplasms;medical schools;meetings;member;Molecular;Multiple Myeloma;Mus;Mutate;Mutation;Myeloproliferative disease;neoplastic cell;next generation;novel;novel therapeutics;nucleocytoplasmic transport;Oral;Pathway interactions;Patient-Focused Outcomes;Patients;Pediatric Oncology;Peer Review;Pentas;Phase;Process;Productivity;programs;Publications;Publishing;Refractory;Relapse;Reporting;Research;Research Personnel;Resource Sharing;Resources;Role;Science;Scientific Advances and Accomplishments;Scientist;Signal Transduction;stem cell biology;Testing;Therapeutic;Tissue Banks;Toxic effect;Transgenic Organisms;Translating;transport inhibitor;ubiquitin-protein ligase;working group

PROJECT_TITLE: Hematologic Malignancies Program


NIH_SPENDING_CATS: Cancer;Digestive Diseases;Liver Cancer;Liver Disease;Rare Diseases

ORG_CITY: LA JOLLA

ORG_NAME: UNIVERSITY OF CALIFORNIA, SAN DIEGO

PHR: Liver cancer is now escalated to be a primary cause in cancer-related deaths worldwide, with no effective pharmaceutical or immune therapies available to treat liver cancer patients. The goal of this project is to better understand the complexity in the pathogenic process and therefore help develop novel therapeutic strategies for the deadly malignant disease.

PI_NAMEs: FENG, GEN-SHENG  (contact)

PROGRAM_OFFICER_NAME: XU, WANPING

PROJECT_TERMS: Ablation;Animal Model;Automobile Driving;BAY 54-9085;beta catenin;cancer type;Cells;Cessation of life;chemical carcinogen;Chemicals;Clinical;Complement;Data;design;Diethylnitrosamine;Disease;Environment;Environmental Risk Factor;Epidermal Growth Factor Receptor;Excision;experimental study;genetic analysis;Goals;Hepatic;Hepatocarcinogenesis;Hepatocyte;Human;Immunotherapy;interdisciplinary approach;kinase inhibitor;Liver;liver cancer model;liver cancer patient;liver inflammation;liver injury;Malignant - descriptor;Malignant neoplasm of liver;Malignant Neoplasms;Modeling;Molecular;mouse model;Mus;NF-kappa B;novel;novel therapeutic intervention;Oncogenes;Oncogenic;Oncoproteins;Oxidative Stress;Paper;Pathogenicity;Pathway interactions;Patients;Pharmacologic Substance;Pharmacy (field);Phenotype;PIK3CA gene;Play;Primary carcinoma of the liver cells;Process;Proteins;Publishing;Research;Role;Sampling;Signal Pathway;Signal Transduction;single-cell RNA sequencing;Sister;Testing;theories;Therapeutic;therapeutically effective;TP53 gene;Transfection;tumor;Tumor Promotion;Tumor Suppressor Proteins;tumorigenesis;tumorigenic

PROJECT_TITLE: Intra- and inter-cellular signals that drive hepato-oncogenesis

STUDY_SECTION: MONC

STUDY_SECTION_NAME: Molecular Oncogenesis Study Section[MONC]


NIH_SPENDING_CATS: Basic Behavioral and Social Science;Behavioral and Social Science;Brain Disorders;Chronic Pain;Clinical Research;Headaches;Migraine;Neurosciences;Pain Research

PHR: Project Narrative  For the millions of individuals who experience migraine each year, treatment typically consists of reactively treating attacks only after experiencing disruptive pain and secondary symptoms. Because individual migraine attacks are unpredictable to most sufferers, efforts to make future attacks more predictable will enhance treatment effectiveness and reduce suffering. This project will create a new forecasting model that predicts the risk of future migraine attacks for an individual person.

PI_NAMEs: HOULE, TIMOTHY T (contact)

PROGRAM_OFFICER_NAME: OSHINSKY, MICHAEL L

PROJECT_TERMS: American;base;Bayesian Forecast;Bayesian Method;Calibration;Clinical;clinically relevant;Data;diaries;Discrimination;Disease;Equilibrium;Estimation Techniques;Exhibits;experience;Frequencies;Future;Goals;Headache;Hour;improved;Individual;Intercept;Laboratories;Learning;Literature;Machine Learning;Measurement;Migraine;Modeling;Moods;neuromechanism;Online Systems;Pain;Parameter Estimation;Participant;Patient Self-Report;perceived stress;Performance;Persons;Pharmaceutical Preparations;Population Heterogeneity;predictive modeling;prevent;Probability;Procedures;Rain;Research Personnel;Resolution;Risk;risk prediction;risk prediction model;Sleep;Specific qualifier value;Statistical Models;Stress;Symptoms;System;Testing;theories;Treatment Effectiveness;Uncertainty;Update;Weather;Weight

PROJECT_TITLE: Forecasting Migraine Attacks

STUDY_SECTION: BMHO

STUDY_SECTION_NAME: Biobehavioral Medicine and Health Outcomes Study Section[BMHO]


ORG_CITY: COLD SPRING HARBOR

ORG_NAME: COLD SPRING HARBOR LABORATORY

PHR: OVERALL PROJECT NARRATIVE Dysregulation of transcription and splicing is pervasive across all human cancers, however very few approved therapies exist that target these processes. This Program Project seeks address this deficiency through target discovery, validation, and deep mechanistic investigation. The insights gained through this research are likely to reveal highly specific, new vulnerabilities in cancer cells that will be the basis of innovative drug development in the fight against cancer.

PI_NAMEs: VAKOC, CHRISTOPHER  (contact)

PROGRAM_OFFICER_NAME: MAAS, STEFAN

PROJECT_TERMS: Address;aerobic glycolysis;Alternative Splicing;Animal Model;Anti-sense RNA;Antisense Oligonucleotide Therapy;Antisense Oligonucleotides;Basic Cancer Research;Basic Science;biobank;Biochemical;Biochemistry;Biological Assay;Biology;Breast Carcinoma;Cancer Biology;cancer cell;cancer therapy;Cellular biology;Chromatin;Clinic;Collaborations;Complex;convict;Creativeness;Dependence;Development;Disease;DNA Binding;DNA Tumor Viruses;DNA-Binding Proteins;Drug Combinations;drug development;drug discovery;Event;fighting;Foundations;Gene Expression;Genes;Genetic Screening;Genetic Transcription;Genome;Goals;Heart;Human;human model;imaging modality;innovation;insight;Intervention;Investigation;Knowledge;MALAT1 gene;Malignant Breast Neoplasm;Malignant neoplasm of pancreas;Malignant Neoplasms;Mammary Neoplasms;Mass Spectrum Analysis;member;Methods;Molecular;Molecular Biology;mRNA Precursor;Nature;Neoplasm Metastasis;new therapeutic target;novel;novel therapeutic intervention;Oncogenes;Oncogenic;Oncogenic Viruses;Organoids;Output;Pancreatic carcinoma;Pancreatic Ductal Adenocarcinoma;Pathogenesis;Pathway interactions;Patients;pharmacologic;Process;Productivity;programs;Protein Isoforms;Proteins;Pyruvate Kinase;reconstitution;Regulation;Research;Research Personnel;RNA;RNA Splicing;Role;Services;small molecule;standard of care;Technology;Testing;Therapeutic;therapeutic development;Time;tool;Touch sensation;transcription factor;tumor;tumor growth;tumor initiation;tumor progression;Tumor Promotion;Tumor Suppressor Proteins;tumorigenesis;Untranslated RNA;Up-Regulation;Validation;Work;Xenograft Model

PROJECT_TITLE: Targeting Transcription and Splicing in Cancer


NIH_SPENDING_CATS: Biotechnology;Breast Cancer;Cancer;Cancer Genomics;Digestive Diseases;Genetics;Human Genome;Orphan Drug;Pancreatic Cancer;Rare Diseases;Women's Health Research

PHR: PROJECT 1 – TARGETING ONCOGENIC TRANSCRIPTION FACTORS PROJECT NARRATIVE Specific oncogenic transcription factor complexes have been identified by this Project as therapeutic opportunities in aggressive carcinomas of the pancreas and breast. To exploit these targets for cancer therapy, we will employ the latest innovations in genome editing technology and biochemistry to elucidate `druggable' interactions involving these factors. A major thematic focus of this work will be to leverage RNA biology and signaling interactions to allow for pharmacological modulation of oncoproteins.

PROJECT_TERMS: addiction;Antisense Oligonucleotides;Area;Binding;biobank;Biochemical;Biochemistry;Biological Assay;Biology;Breast Carcinoma;Bypass;cancer cell;cancer genome;cancer therapy;Carcinoma;CHD4 gene;chemical genetics;Chemicals;cofactor;Collaborations;Complex;conditional knockout;CRISPR screen;Data;Dependence;Disease;disease prognosis;DNA Binding;drug development;drug discovery;Enhancers;Epigenetic Process;epigenomics;Epithelial Cells;Epithelium;Experimental Genetics;experimental study;Foundations;Funding;Future;Genes;Genetic;Genetic Epistasis;Genetic Screening;Genetic Transcription;genome editing;Goals;Homeostasis;Human;Hydrophobicity;in vivo;inhibitor;innovation;insight;Investigation;Knock-out;Knowledge;Laboratories;Ligands;Link;Maintenance;Malignant - descriptor;Malignant Breast Neoplasm;Malignant Epithelial Cell;Malignant neoplasm of pancreas;Malignant Neoplasms;Maps;Medicine;Messenger RNA;Metastatic Carcinoma;Methods;Modeling;molecular oncology;Mus;novel;nucleic acid binding protein;Oncogenic;Oncology;Oncoproteins;Organoids;Pancreatic carcinoma;paralogous gene;Pathway interactions;Peptides;Perception;pharmacologic;Pharmacology;phosphoproteomics;Phosphotransferases;Post-Transcriptional Regulation;predictive marker;Proteins;Reporter;Research;RNA;RNA Binding;RNA Splicing;RNA-Binding Proteins;RNA-Protein Interaction;Role;SAGA;screening;Screening Result;self-renewal;Signal Pathway;Signal Transduction;small molecule;Specificity;targeted cancer therapy;Technology;Testing;Therapeutic;therapeutic development;Therapeutic Index;Tissues;tool;Transcription Coactivator;transcription factor;Transcriptional Regulation;transcriptome;Transgenic Mice;tumor;Tumor Subtype;Untranslated RNA;Work;Zinc Fingers

PROJECT_TITLE: Project 1: Targeting Oncogenic Transcription Factors


NIH_SPENDING_CATS: Biotechnology;Brain Cancer;Brain Disorders;Cancer;Cancer Genomics;Childhood Leukemia;Gene Therapy;Genetics;Hematology;Human Genome;Immunotherapy;Neuroblastoma;Neurosciences;Orphan Drug;Pediatric;Pediatric Cancer;Precision Medicine;Rare Diseases;Transplantation

PI_NAMEs: GRUPP, STEPHAN A. (contact)

PROJECT_TERMS: Achievement;Acute;Acute Lymphocytic Leukemia;Adult Acute Lymphocytic Leukemia;Allogenic;Amaze;Antibody-drug conjugates;Area;B-Cell Acute Lymphoblastic Leukemia;Basic Science;Behavioral;bench to bedside;Biology;Brain Neoplasms;Cancer Center;Cancer Center Support Grant;Cancer Control;cancer genomics;CAR T cell therapy;Catchment Area;CD19 gene;Cell Therapy;Cell Transplantation;Cellular biology;chemotherapy;Chief Cell;Child;Childhood;Childhood Acute Lymphocytic Leukemia;Childhood Leukemia;Childhood Solid Neoplasm;chimeric antigen receptor;chimeric antigen receptor T cells;clinical development;clinical investigation;Clinical Pharmacology;Clinical Research;Clinical Trials;Collaborations;Communities;crizotinib;cytokine release syndrome;Data Set;Development;Disease;Doctor of Philosophy;drug development;Educational Activities;engineered T cells;Ensure;Epidemiology;Evaluation;FDA approved;Frequencies;fundamental research;Funding;gene therapy;Genomic approach;genomic data;Genomics;Glioma;Goals;Grant;Hematologic Neoplasms;high risk;Immunobiology;Immunogenomics;Immunotherapy;improved;inhibitor;innovation;Institution;Interleukin-6;International;Intervention Trial;Ki-1 Large-Cell Lymphoma;kinase inhibitor;Laboratories;large scale data;Leadership;Lesion;leukemia;Life;Malignant Childhood Neoplasm;Malignant neoplasm of brain;Malignant Neoplasms;medical schools;Medicine;member;mid-career faculty;Molecular;Multicenter Trials;Nature;neoplasm immunotherapy;Neuroblastoma;Newly Diagnosed;novel;novel diagnostics;novel strategies;novel therapeutic intervention;novel therapeutics;Oncology;oncology program;Pathogenesis;Pathway interactions;Patients;Pediatric Oncology;Pediatric Oncology Group;Pediatrics;Peer Review;Pharmaceutical Preparations;Philadelphia;Phosphotransferases;Physician Executives;Play;Precision therapeutics;preclinical development;Predisposition;professor;programs;Protocols documentation;Publications;recruit;Relapse;Research;Research Personnel;Risk;Role;Sarcoma;Signal Transduction;Solid Neoplasm;standard of care;Stem cell transplant;success;survivorship;Systems Biology;T cell therapy;targeted treatment;Testing;Therapeutic;Toxic effect;Translating;Translational Research;tumor;Tumor Biology;tumor immunology;Work;young adult

PROJECT_TITLE: Pediatric Oncology Program


NIH_SPENDING_CATS: Biotechnology;Breast Cancer;Cancer;Digestive Diseases;Genetics;Orphan Drug;Pancreatic Cancer;Rare Diseases;Women's Health Research

PHR: PROJECT 2 – RNA-SPLICING DYSREGULATION IN CANCER PROJECT NARRATIVE RNA splicing is a fundamental step in the normal function of genes. In cancer cells, this process is altered in ways that can contribute to tumor growth. By studying dysregulated splicing in cancer, unique vulnerabilities of cancer cells will be uncovered, and potential therapeutic targets revealed.

PI_NAMEs: KRAINER, ADRIAN R (contact)

PROJECT_TERMS: Acceleration;aerobic glycolysis;Affect;Alternative Splicing;Antisense Oligonucleotide Therapy;Antisense Oligonucleotides;Antisense Technology;Breast Epithelial Cells;cancer cell;Cancer Model;Carcinoma;Cell Reprogramming;cell transformation;cell type;Cells;Cellular Metabolic Process;Chemicals;Clinical;Computer Analysis;Dependence;Ductal Epithelial Cell;Event;Exhibits;Exons;Future;gene function;Genes;Genetic;Genetic Transcription;Goals;High-Throughput RNA Sequencing;Human;IL1R1 gene;In Vitro;in vivo;in vivo Model;Individual;Investigation;KRAS2 gene;Malignant Breast Neoplasm;Malignant neoplasm of pancreas;Malignant Neoplasms;Mammary gland;mammary gland development;MDM2 gene;Mediating;Modeling;Modification;mouse model;mRNA Precursor;mutant;Mutation;Neoplasm Metastasis;Normal Cell;Oncogenes;Oncogenic;Oncoproteins;Organoids;overexpression;pancreatic cancer model;Pancreatic duct;Pancreatic Ductal Adenocarcinoma;pancreatic ductal adenocarcinoma model;Pathway interactions;Phenotype;posttranscriptional;pre-clinical;Process;Protein Isoforms;Proteins;Pyruvate Kinase;receptor;Recurrence;Regulation;RNA Splicing;RNA-Binding Proteins;Role;Route;Scaffolding Protein;senescence;Site;Spliced Genes;Spliceosome Assembly Pathway;Spliceosomes;targeted treatment;Testing;Therapeutic;therapeutic evaluation;therapeutic target;three dimensional cell culture;TP53 gene;Transcriptional Regulation;tumor;tumor growth;tumor metabolism;tumorigenesis;Untranslated RNA;Up-Regulation;uptake;Warburg Effect;Work

PROJECT_TITLE: Project 2: Splicing Dysregulation in Cancer


NIH_SPENDING_CATS: Cancer;Hematology;Immunotherapy;Stem Cell Research;Stem Cell Research - Nonembryonic - Non-Human

ORG_NAME: BETH ISRAEL DEACONESS MEDICAL CENTER

PHR: Activation of the immune system by immunotherapy can be used for the treatment of cancer but major gaps in our knowledge compromise optimal outcomes. This project will study how immunotherapy affects the differentiation of myeloid cells, a major component of the innate immune system, and their ability to crosstalk with T lymphocytes and attack cancer. This work may significantly improve the outcome of immunotherapy and provide a major benefit to cancer patients.

PI_NAMEs: BOUSSIOTIS, VASSILIKI A (contact)

PROGRAM_OFFICER_NAME: KUO, LILLIAN S

PROJECT_TERMS: Ablation;Affect;anti-cancer therapeutic;Antibodies;ATAC-seq;B-Lymphocytes;Biogenesis;Blocking Antibodies;cancer cell;Cancer Patient;cancer therapy;CD8-Positive T-Lymphocytes;Cell Differentiation process;Cell Lineage;Cell Physiology;Cells;ChIP-seq;cholesterol biosynthesis;Clinical Trials;Dendritic Cells;Development;Emergency Situation;Environment;Epigenetic Process;FRAP1 gene;Generations;Genes;Genetic;glucose uptake;granulocyte;Growth Factor Receptors;Hematopoietic;Hematopoietic stem cells;IL17 gene;Immune;immune activation;Immune system;Immunity;Immunologics;Immunotherapy;improved outcome;inhibitor;Innate Immune System;ITGAM gene;Knockout Mice;Knowledge;Lead;Ligands;Macrophage;Malignant Neoplasms;Mediating;Metabolic;Metabolism;metabolomics;mevalonate;Mitochondria;Modeling;Molecular;monocyte;Mus;Myelogenous;Myeloid Cells;Myeloid Progenitor Cells;Myeloid-derived suppressor cells;Myelopoiesis;novel;Outcome;Output;pathogen;Pathway interactions;Patients;PD-1 blockade;PD-1 pathway;PDL1 pathway;pharmacologic;Phosphorylation;preservation;prevent;progenitor;programmed cell death ligand 1;programmed cell death protein 1;programs;Property;Regulatory T-Lymphocyte;response;Role;Signal Transduction;stable isotope;Stress;success;T cell response;T-Lymphocyte;terminally differentiated effector memory (TEM) T cells;Training;transcriptome sequencing;tumor;tumor growth;Tumor Immunity;tumor microenvironment;Work

PROJECT_TITLE: The effects of PD-1 on tumor-mediated “emergency” myelopoiesis and fate commitment of myeloid cells: Implications for anti-tumor immunity

STUDY_SECTION: CII

STUDY_SECTION_NAME: Cancer Immunopathology and Immunotherapy Study Section[CII]


ORG_NAME: UNIVERSITY OF PENNSYLVANIA

PI_NAMEs: GADE, TERENCE P (contact)

PROJECT_TERMS: Address;anti-cancer;Basic Science;Biological;Cancer Burden;cancer care;Cancer Center Support Grant;Cancer Control;Cancer Patient;cancer therapy;Catchment Area;checkpoint therapy;chimeric antigen receptor T cells;Clinical;Clinical Research;Clinical Trials;Collaborations;community collaboration;community engagement;Community Outreach;Consultations;Department chair;design,build,test;Development;Direct Costs;Discipline of Nuclear Medicine;Disease;Doctor of Philosophy;Education and Outreach;Ensure;Environment;environmental carcinogenesis;epidemiology study;Funding;Goals;Hypoxia;Image;imaging agent;imaging biomarker;Imaging Device;imaging modality;imaging program;Immune;Immune checkpoint inhibitor;Immune response;Immune system;Immunobiology;Immunotherapy;improved;innovation;Institution;Intervention;Intervention Trial;investigator-initiated trial;Ionizing radiation;Lead;Leadership;Malignant Breast Neoplasm;Malignant Neoplasms;member;Metabolic stress;mid-career faculty;Modality;Nonionizing Radiation;Normal tissue morphology;novel;nuclear division;optimal treatments;Patient-Focused Outcomes;Patients;Pediatric Oncology;Peer Review;Play;professor;programs;proton beam;proton therapy;Protons;Publications;Radiation;Radiation Oncology;Radiation therapy;Radiation Tolerance;Radiobiology;Radiology Specialty;Radiopharmaceuticals;recruit;Research;research and development;Research Personnel;Research Project Grants;Resolution;Resource Sharing;Resources;response;Role;Schools;Senior Scientist;Technology;Testing;theranostics;Therapeutic;Time;tobacco carcinogenesis;translational pipeline;Translational Research;translational study;treatment response;Tumor Biology;tumor metabolism;tumor microenvironment;Tumor Tissue;Vision;Work

PROJECT_TITLE: Radiobiology and Imaging Program


ADMINISTERING_IC: AG

IC_NAME: NATIONAL INSTITUTE ON AGING

NIH_SPENDING_CATS: Acquired Cognitive Impairment;Aging;Alzheimer's Disease;Alzheimer's Disease Related Dementias (ADRD);Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD);Brain Disorders;Dementia;Frontotemporal Dementia (FTD);Genetics;Neurodegenerative;Neurosciences

ORG_CITY: SEATTLE

ORG_NAME: SEATTLE INST FOR BIOMEDICAL/CLINICAL RES

ORG_STATE: WA

PHR: Pathological tau protein accumulates as lesions in neurons of patients with Alzheimer's disease and Alzheimer's Disease Related Dementia disorders. Aberrant tau causes neuronal dysfunction and neurodegeneration. Tauopathy disorders have no effective treatment, are progressive, and ultimately cause premature death. The molecular basis underlying the neurotoxicity of pathological tau remains poorly understood. Our previous studies have demonstrated the unfolded protein response can detoxify pathological tau. Completion of the proposed work will inform the molecular mechanisms of tau mediated neurodegeneration setting the stage for future translational studies.

PI_NAMEs: KRAEMER, BRIAN C. (contact)

PROGRAM_OFFICER_NAME: LI, TONG

PROJECT_TERMS: Address;Aging;aging related;Alzheimer's Disease;Alzheimer's disease model;Alzheimer's disease patient;Alzheimer's disease related dementia;Animal Model;Animals;ATF6 gene;Bioinformatics;Brain;brain tissue;Caenorhabditis elegans;Cellular Stress;Cessation of life;Dementia;Deposition;Diagnostic;Disease;disease model;Drug Metabolic Detoxication;effective therapy;Endoplasmic Reticulum;endoplasmic reticulum stress;Exhibits;Frontotemporal Lobar Degenerations;Functional disorder;Future;Genes;Genetic Transcription;genome wide association study;Goals;Human;human disease;hyperphosphorylated tau;Laboratories;Lesion;Mammals;Mediating;misfolded protein;Modeling;Molecular;Molecular Genetics;Molecular Target;mouse model;Nerve Degeneration;Neurodegenerative Disorders;Neurofibrillary Tangles;Neuronal Dysfunction;Neurons;neuroprotection;neurotoxicity;Pathologic;Pathology;Patients;Phenotype;premature;Progressive Supranuclear Palsy;Protein Isoforms;Proteins;response;response biomarker;Role;System;tau aggregation;tau mutation;tau Proteins;Tauopathies;Testing;Toxic effect;transcriptomics;transgene expression;Transgenes;Transgenic Model;Transgenic Organisms;translational potential;translational study;Work;XBP1 gene

PROJECT_TITLE: Protection from pathological tau by activation of the ER unfolded protein response

STUDY_SECTION: CMND

STUDY_SECTION_NAME: Cellular and Molecular Biology of Neurodegeneration Study Section[CMND]


ORG_CITY: CLEVELAND

ORG_DEPT: PHYSIOLOGY

ORG_NAME: CASE WESTERN RESERVE UNIVERSITY

ORG_STATE: OH

PHR: One of the major tasks of red blood cells (RBCs) is to carry oxygen from the lungs to tissues throughout the body. The goals include the discovery of membrane protein channels responsible for the movement of oxygen into or out of RBCs. Another goal is to understand how the absence of these channels causes experimental animals have greater exercise efficiency. Achieving these goals could have a major positive impact for patients with an impaired ability to carry oxygen from the lungs to their tissues (e.g., reduced exercise in heart failure).

PI_NAMEs: BORON, WALTER F (contact)

PROGRAM_OFFICER_NAME: QASBA, PANKAJ

PROJECT_TERMS: 3-Dimensional;Address;Affect;Age;Aging;Air;Alveolar;Amino Acid Sequence;Animal Experiments;AQP1 gene;Biological Assay;Biology;Biophysics;Blood;Blood capillaries;Carbon Dioxide;Cardiovascular system;cell dimension;Cell membrane;Cell Membrane Proteins;Cell Shape;Cell Size;cell type;Cells;Collaborations;Complex;Consumption;COVID-19;Data;Data Analyses;Diffusion;Disease;disease model;Dissociation;Erythrocytes;Exercise;exercise capacity;Exhibits;experimental study;extracellular;falls;follow-up;Gases;Gene Modified;Genetic;Genetic Polymorphism;Genomics;Genotype;Geometry;Goals;Grant;Health;Heart failure;Hematology;Hemoglobin;Human;human disease;human model;hypoperfusion;Impairment;improved;Indirect Calorimetry;inhibitor;insertion/deletion mutation;insight;Interdisciplinary Study;Ion Channel;Kinetics;Knock-out;Knockout Mice;Laboratories;Libraries;Life;lipidomics;Lipids;Liquid substance;Lung;Lung Diseases;mathematical model;Measures;Membrane;Membrane Lipids;Membrane Proteins;Metabolic;Molecular;molecular dynamics;mouse model;Mouse Strains;Movement;Mus;Muscle;mutant;Mutation;Mutation Analysis;Nature;novel;Oocytes;Oxygen;Oxyhemoglobin;Pathway interactions;Patients;Performance;Permeability;Plasma Cells;Play;premature;Process;Proteins;Proteomics;Protocols documentation;public health relevance;Reaction;Research;Research Personnel;Resistance;Rhesus;Role;Running;Sepsis;Single Nucleotide Polymorphism;Sodium Dithionite;Speed;Structural Biologist;Systems Biology;Testing;Thinking;Thinness;Tissues;tool;treadmill;uptake;Vascular Diseases;water channel;Work

PROJECT_TITLE: Mechanisms of oxygen off-loading from red blood cells in murine models of human disease

STUDY_SECTION: BBHV

STUDY_SECTION_NAME: Basic Biology of Blood, Heart and Vasculature Study Section [BBHV]


ORG_NAME: SLOAN-KETTERING INST CAN RESEARCH

PHR: PROJECT NARRATIVE BRAF-mutant anaplastic thyroid cancers are almost always incurable and frequently lethal. They are heavily infiltrated by myeloid and T cells. We propose to investigate the relative contribution of myeloid cell depletion and antigen presentation by tumor cells in their remarkable response to MAPK inhibition, because they point to ATC vulnerabilities that could be targeted through alternative approaches, as well as to eventual mechanisms of resistance to this therapy.

PI_NAMEs: FAGIN, JAMES A (contact)

PROGRAM_OFFICER_NAME: BOURCIER, KATARZYNA

PROJECT_TERMS: Affect;anaplastic thyroid cancer;Antigen Presentation;Antigen Presentation Pathway;Antigen-Presenting Cells;Antigens;Attenuated;BRAF gene;cancer cell;Cells;chemotherapy;Chromatin Remodeling Factor;Combined Modality Therapy;cytokine;cytotoxic;Cytotoxic Chemotherapy;cytotoxicity;derepression;Disease;Distant Metastasis;DNA Sequence Alteration;Genes;Genetic;Genetic Suppression;Growth;Human;human disease;Immune;immune checkpoint blockade;Immune Targeting;Immunologic Surveillance;Immunologics;Immunosuppression;in vivo;Individual;inducible gene expression;Infiltration;inhibitor;Leukocytes;Macrophage;Maintenance;Malignant neoplasm of thyroid;Malignant Neoplasms;MAP Kinase Gene;MEKs;Microsatellite Instability;Modeling;monocyte;mortality;mouse model;Mus;mutant;Mutation;Myelogenous;Myeloid Cells;Myeloid-derived suppressor cells;Neck;neoantigens;neoplastic cell;older patient;Oncogenic;Operative Surgical Procedures;Pathway interactions;Patients;PD-1 blockade;PD-1 inhibitors;pharmacologic;Phenocopy;pilot trial;Play;Population;Process;Production;Prognosis;programs;Property;Radiation;recruit;Regulation;Regulatory Pathway;resistance mechanism;response;Role;Signal Transduction;T cell response;T-Lymphocyte;Testing;Therapeutic;therapy resistant;Thyroid Gland;TP53 gene;treatment response;tumor;Tumor-associated macrophages;Tumor-Derived;Up-Regulation

PROJECT_TITLE: Targeting immune suppressive microenvironment in ATC

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1-OTC-M(08)F]


NIH_SPENDING_CATS: Biotechnology;Breast Cancer;Cancer;Genetics;Human Genome;Women's Health Research

ORG_DEPT: BIOCHEMISTRY

ORG_NAME: COLUMBIA UNIVERSITY HEALTH SCIENCES

PHR: Project Narrative Homologous recombination is a DNA repair pathway, which plays crucial roles in genetic disorders, cancer and aging. Several tumor suppressor proteins are now known to participate in homologous recombination, and defects in these proteins are broadly associated with human cancers. Included among these are BRCA1 and BRCA2, which are key proteins involved in the early stages of homologous recombination, and are frequently mutated in hereditary breast and ovarian cancers. To help extend our understanding of how BRCA1 and BRCA2 participate in homologous recombination we have developed a powerful new experimental platform based on state-of-the-art optical microscopy that enables us to directly observe the proteins that participate in homologous recombination in real time. These powerful new research tools allow us to address questions in cancer research that cannot be tackled with more traditional experimental approaches.

PI_NAMEs: GREENE, ERIC C (contact)

PROGRAM_OFFICER_NAME: WITKIN, KEREN L

PROJECT_TERMS: Address;Affect;Aging;anti-cancer research;anti-cancer therapeutic;Antineoplastic Agents;BARD1 gene;Binding;Biological Assay;BRCA1 gene;BRCA2 gene;BRCA2 Mutation;cancer cell;cancer therapy;Cells;Characteristics;chemotherapy;Chromosomal Rearrangement;Chromosomes;Clinical;Complex;Defect;defined contribution;Dependence;Development;Disease;DNA;DNA biosynthesis;DNA Double Strand Break;DNA Repair;DNA Repair Pathway;DNA replication fork;DNA Sequence;DNA strand break;Event;Exhibits;experimental study;Filament;Future;Genetic Diseases;genetic information;Genetic Recombination;genome integrity;Genome Stability;Goals;Hereditary Breast and Ovarian Cancer Syndrome;homologous recombination;Human;Human Biology;human disease;human DNA;Human Genome;human imaging;Individual;inhibitor;insight;Macromolecular Complexes;Malignant Breast Neoplasm;Malignant Neoplasms;Mediating;Microscopy;Molecular;Mutate;Normal Cell;Nucleic Acids;Nucleoproteins;Optics;Outcome;PALB2 gene;Pathway interactions;Patients;Play;Poly(ADP-ribose) Polymerase Inhibitor;Predisposition;presynaptic;prevent;Process;Property;protein complex;Proteins;RAD52 gene;Reaction;Regulation;Repair Complex;repaired;Research;Resistance;Role;single molecule;Single-Stranded DNA;Source;spatiotemporal;Syndrome;therapeutic target;Time;time use;tool;Tumor Suppression;Tumor Suppressor Proteins;Visualization;Work

PROJECT_TITLE: Defining the contributions of BRCA1, BRCA2, and RAD52 to genome stability

STUDY_SECTION: MSFC

STUDY_SECTION_NAME: Macromolecular Structure and Function C Study Section[MSFC]


NIH_SPENDING_CATS: Biotechnology;Breast Cancer;Cancer;Digestive Diseases;Genetics;Pancreatic Cancer;Rare Diseases;Women's Health Research

PHR: PROJECT 3 – REGULATORY RNAS AS CANCER DRIVERS AND DEPENDENCIES PROJECT NARRATIVE Project 3 will characterize the function of several long non-coding RNAs that are over-expressed in basal-like triple negative breast cancer (TNBC) and basal-like pancreatic ductal adenocarcinoma (PDAC). The impact of antisense oligonucleotide knockdown on cancer progression and metastasis will be studied using patient-derived organoid xenograft models. Insights gained from this study will significantly impact considerations of new therapeutic approaches to treat basal-like TNBC and basal-like PDAC.

PI_NAMEs: SPECTOR, DAVID L (contact)

PROJECT_TERMS: Actins;Angiogenesis Pathway;anti-sense nucleic acid;Anti-sense RNA;Antisense Oligonucleotide Therapy;Antisense Oligonucleotides;Binding;biobank;Biology;Breast;Breast Cancer Patient;breast cancer progression;Breast Epithelial Cells;Cancer Biology;cancer therapy;cancer type;Cell Nucleus;Cell Proliferation;chemotherapy;Chromatin;Chromatin Structure;Clinical Trials;cohort;Complex;Coupled;CRISPR screen;Cytoskeleton;deep sequencing;Dependence;Disease;Drug resistance;ERBB2 gene;Extracellular Matrix;Fractionation;Gene Expression;Gene Expression Regulation;Genes;Genetic Transcription;Goals;Human;Human Genome;in vivo;innovation;insight;Invaded;knock-down;Knock-out;Laboratories;Lung Adenocarcinoma;MALAT1 gene;Malignant Breast Neoplasm;Malignant neoplasm of pancreas;Malignant Neoplasms;Mammary Neoplasms;Mass Spectrum Analysis;Mediating;migration;Modeling;Molecular;Molecular Chaperones;mRNA Precursor;Neoplasm Metastasis;novel;novel therapeutic intervention;Nuclear RNA;nucleic acid-based therapeutics;Nucleic Acids;Nucleotides;Organoids;Orthologous Gene;Outcome;overexpression;Pancreatic Ductal Adenocarcinoma;patient prognosis;Patient-Focused Outcomes;Patients;Pharmaceutical Preparations;Play;Poly(A)+ RNA;Population;Primary Neoplasm;Proliferating;Proteins;recruit;RNA;RNA purification;RNA Splicing;Role;scaffold;Series;Signal Transduction;standard of care;tensin;Therapeutic;therapeutic target;Transcript;Transcription Coactivator;transcriptome;treatment response;triple-negative invasive breast carcinoma;tumor;tumor growth;tumor progression;Tumor Subtype;Untranslated RNA;Xenograft Model

PROJECT_TITLE: Project 3: Regulatory RNAs as Cancer Drivers and Dependencies


NIH_SPENDING_CATS: Behavioral and Social Science;Cancer;Cancer Genomics;Clinical Research;Genetics;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Health Services;Human Genome;Lung;Lung Cancer;Pediatric;Prevention;Social Determinants of Health;Tobacco;Tobacco Smoke and Health

PI_NAMEs: GLANZ, KAREN  (contact)

PROJECT_TERMS: Abbreviations;Academy;acronyms;Address;Adult;Affect;Animals;Area;Basic Science;Behavioral;Behavioral Sciences;biobank;Bioethics;Bioinformatics;Biometry;Biostatistics Shared Resource;Breast Cancer gene;Businesses;Cancer Burden;cancer care;Cancer Center;Cancer Center Support Grant;Cancer Control;Cancer Etiology;cancer genomics;cancer health disparity;Cancer Model;cancer risk;Cancer Survivor;Cancer Survivorship;cancer therapy;care outcomes;Caring;Catchment Area;Childhood;Clinical;Clinical Management;Clinical Medicine;clinical practice;Clinical Research;Clinical Trials;Cognitive Science;Collaborations;Colorectal Cancer;Communication;communication behavior;Communities;community engaged research;community engagement;Community Outreach;comparative efficacy;Comparative Pathology;Data Analytics;Detection;Diet;Disparity;Early Diagnosis;Economics;Education;Electronic Health Record;Electronics;end of life care;Enrollment;environmental carcinogenesis;Environmental Risk Factor;Epidemiology;Equity;evidence base;Faculty;Funding;Genes;Genetic;Genetic Counseling;Genetic Predisposition to Disease;Genomics;Goals;Grant;Health;Health behavior;Health Policy;Health Services;Healthcare;Hematologic Neoplasms;high school;Image;imaging program;Immunobiology;improved;improved outcome;Incentives;Incidence;Individual;Informatics;innovation;Institution;Interdisciplinary Study;Intervention;Intervention Trial;Investments;Late Effects;Leadership;Malignant Breast Neoplasm;Malignant neoplasm of lung;Malignant Neoplasms;medical schools;member;Mentors;metabolomics;Methods;microbiome;Modeling;Morbidity - disease rate;mortality;next generation;novel;nutrition;Obesity;Outcome;Patient-Centered Care;Patient-Focused Outcomes;Pediatric Hospitals;Pediatric Oncology;Peer Review;Penetrance;Pennsylvania;Phenotype;Philadelphia;Population;population health;Population Heterogeneity;Population Sciences;pragmatic trial;Predisposition;Prevention;Productivity;programs;Public Health;Publications;Quality of life;Radiation;Radiobiology;recruit;Research;Research Personnel;Resources;Risk;Risk Factors;risk variant;School Nursing;Schools;Science;Science of genetics;Scientific Inquiry;Screening for cancer;Social Psychology;Social Sciences;survivorship;telehealth;Testicular Germ Cell Tumor;Therapeutic;tobacco carcinogenesis;tobacco control;Training;Translating;treatment disparity;treatment trial;Universities;Vulnerable Populations;Work

PROJECT_TITLE: Cancer Control Program

STUDY_SECTION: NCI

STUDY_SECTION_NAME: Cancer Centers Study Section (A)[NCI-A]


NIH_SPENDING_CATS: Cancer;Clinical Research;Clinical Trials and Supportive Activities;Digestive Diseases;Orphan Drug;Pancreatic Cancer;Rare Diseases;Stem Cell Research;Stem Cell Research - Nonembryonic - Non-Human

ORG_CITY: OMAHA

ORG_NAME: UNIVERSITY OF NEBRASKA MEDICAL CENTER

ORG_STATE: NE

PHR: Project Narrative Heterogeneous and inadequate blood flow and obstructive stroma in pancreatic tumor microenvironment (TME) are the critical determinants of extrinsic resistance while cancer stem cells contribute to intrinsic resistance to chemotherapy and selective targeting of these barriers can significantly enhance the delivery and efficacy of chemotherapeutic agents. We propose to undertake studies to target endothelin axis using selective and clinically-tested antagonists with a goal to improve the efficacy of GEM/ABX using preclinical models of pancreatic cancer. Further, we propose to evaluate the safety of ET-axis antagonist bosentan in combination with FDA approved combination of chemotherapeutic agents (Abraxane and Gemcitabine- GEM/ABX) in pancreatic cancer patients in a Phase I trial with a goal to generate meaningful data for a future Phase I/II clinical trials.

PI_NAMEs: BATRA, SURINDER K.;JAIN, MANEESH  (contact);SALGIA, RAVI

PROGRAM_OFFICER_NAME: OLKHANUD, PUREVDORJ BALJINNYAM

PROJECT_TERMS: Abraxane;Albumins;Amino Acids;antagonist;Biodistribution;Blood flow;Blood Vessels;bosentan;cancer cell;cancer stem cell;cancer therapy;cell type;Cells;Chemoresistance;chemotherapeutic agent;chemotherapy;Clinical;Clinical Research;Clinical Trials;Coculture Techniques;Combined Modality Therapy;Complex;Consensus;Data;design;Desmoplastic;determinants of treatment resistance;Diffusion;Drug Delivery Systems;Drug Efflux;Drug resistance;druggable target;efficacy evaluation;Endothelin;Endothelin Receptor;Endothelin-1;Endothelin-2;Endothelin-3;Extracellular Matrix;Family;FDA approved;Future;G-Protein-Coupled Receptors;gemcitabine;Genetically Engineered Mouse;Goals;Human;Hypoxia;improved;In Vitro;in vivo;inhibitor;Invaded;KPC model;macromolecule;Malignant neoplasm of pancreas;Malignant Neoplasms;Mediating;Modality;mouse model;Mus;neoplastic cell;Organoids;Outcome;overexpression;Paclitaxel;pancreas xenograft;pancreatic cancer cells;pancreatic cancer model;pancreatic cancer patients;pancreatic neoplasm;pancreatic stellate cell;Pathogenesis;Pathway interactions;Peptides;Perfusion;perineural;permissiveness;Pharmaceutical Preparations;Pharmacodynamics;Phase;phase I trial;Phase I/II Clinical Trial;Phenotype;Population;pre-clinical;Pre-Clinical Model;preclinical evaluation;preclinical study;Radiation therapy;Radiolabeled;Recurrence;Refractory;Regimen;Resistance;Role;Safety;safety assessment;Scheme;screening;Signal Transduction;small molecule;Specificity;stellate cell;stemness;Stromal Cells;Stromal Neoplasm;Testing;Therapeutic;Therapeutic Agents;therapeutically effective;therapy outcome;Toxic effect;Treatment Efficacy;tumor;tumor heterogeneity;tumor microenvironment;uptake;vasoconstriction

PROJECT_TITLE: Modulation of Tumor Microenvironment for Improved Therapy of Pancreatic Cancer

STUDY_SECTION: CONC

STUDY_SECTION_NAME: Clinical Oncology Study Section[CONC]


ED_INST_TYPE: SCHOOLS OF PHARMACY

ORG_CITY: GAINESVILLE

ORG_NAME: UNIVERSITY OF FLORIDA

ORG_STATE: FL

PHR: PROJECT NARRATIVE The proposed research is focus on understanding the causes of variable expression of drug metabolizing enzymes that causes variable drug efficacy and side effects. The results of the proposed research will provide scientific basis for designing accurate genetic biomarkers guiding personalized drug therapy.

PI_NAMEs: WANG, DANXIN  (contact)

PROGRAM_OFFICER_NAME: KODURI, SAILAJA

PROJECT_TERMS: Adopted;Affect;Amino Acid Sequence;Architecture;Bioinformatics;Biological Markers;biomarker discovery;Clinical;clinical biomarkers;clinical translation;clinically significant;cohort;Collaborations;Complex;CYP2D6 gene;CYP3A4 gene;CYP7A1 gene;Cytochrome P450;Dedications;design;drug efficacy;drug metabolism;enzyme activity;Enzymes;Epigenetic Process;ESR1 gene;Funding;Gene Cluster;Gene Expression;Genes;Genetic;Genetic Epistasis;Genetic Markers;genetic variant;Genetic Variation;genome wide association study;Genomics;Goals;Hepatocyte;Human;induced pluripotent stem cell;innovation;insight;Knock-out;Ligands;Liver;Methodology;mRNA Expression;National Institute of General Medical Sciences;new technology;non-genetic;Outcome;Persons;Pharmaceutical Preparations;Pharmacogenetics;Pharmacotherapy;Positioning Attribute;precision drugs;programs;protein expression;Proteomics;Research;Sampling;side effect;success;Testing;Untranslated RNA;Variant

PROJECT_TITLE: Expression genetics of pharmacogenes

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1-CB-T(55)R]


NIH_SPENDING_CATS: Asthma;Lung

ORG_CITY: ANN ARBOR

ORG_NAME: UNIVERSITY OF MICHIGAN AT ANN ARBOR

ORG_STATE: MI

PHR: The development of chronic severe asthma continues to be more completely elucidated to further understand the mechanisms that can be targeted for therapeutic intervention. This proposal will explore the novel processes in order to better understand the genesis of the overall pulmonary disease process, we are focusing on the neonatal studies as well as in later chronic disease to identify interactions of immune mediators that drive structural changes during lung development and repair processes.

PI_NAMEs: LUKACS, NICHOLAS W (contact)

PROGRAM_OFFICER_NAME: LU, QING

PROJECT_TERMS: Address;Airway Disease;Allergens;Allergic;Area;Asthma;asthmatic;Autophagocytosis;Biological Response Modifiers;Cell Physiology;Cells;Cellular Metabolic Process;chemokine;Chronic;Chronic Disease;Chronic lung disease;Clinical;cytokine;Development;Disease;Environment;eosinophil;epigenetic regulation;Functional disorder;Goals;Grant;Immune;immune activation;Immune response;Immunity;immunoregulation;Inflammation;insight;Investigation;Knowledge;Laboratories;Link;Lung;lung development;Lung Diseases;Lung immune response;lung repair;Lymphocyte;Metabolic Control;Metabolism;Mononuclear;mucus hypersecretion;National Heart, Lung, and Blood Institute;Nature;Neonatal;notch protein;novel;Phenotype;Population;Process;pulmonary function;Research;response;Role;Severity of illness;Shapes;Stem Cell Factor;Steroid Resistance;Structure;targeted treatment;Therapeutic;Therapeutic Intervention;therapeutic target;Training;Viral;Viral Respiratory Tract Infection;Work

PROJECT_TITLE: Viral and allergen-driven immunity in chronic lung disease


ORG_CITY: AMHERST

ORG_NAME: STATE UNIVERSITY OF NEW YORK AT BUFFALO

PHR: PROJECT NARRATIVE Inducing high frequencies of CD8+ T cells that kill cancer cells is a goal of immunotherapy, and short peptide vaccines hold the most fundamental biochemical information to do so. We will develop an enabling peptide vaccine adjuvant based on rapid, spontaneous and serum-stable self-assembly of liposomes and peptides, to understand and improve its anti-cancer potency and mechanisms of action for prophylactic, therapeutic and microlibrary screening applications.

PI_NAMEs: ABRAMS, SCOTT I.;LOVELL, JONATHAN F (contact)

PROJECT_TERMS: Address;Adjuvant;Algorithms;anti-cancer;Antibody Response;Antigen-Presenting Cells;antigen-specific T cells;Antigens;Antitumor Response;Binding;Biochemical;Biological;Biological Assay;cancer cell;Cancer cell line;cancer therapy;Cancer Vaccines;CD44 gene;CD8-Positive T-Lymphocytes;CD8B1 gene;cell killing;Cells;Chemicals;Clinical;Cobalt;cost;Cyclophosphamide;cytokine;Data;Dendritic Cells;density;design;Development;Dose;draining lymph node;efficacy evaluation;Environment;Epitopes;Frequencies;Generations;Goals;high throughput screening;Histocompatibility;Immune;immune checkpoint blockade;Immune Targeting;Immunization;Immunize;immunogenic;Immunosuppression;Immunotherapy;improved;in vivo;Inbred BALB C Mice;insight;Laboratories;Length;Libraries;Liposomes;Malignant Neoplasms;Mediating;Memory;Metastatic Neoplasm to the Lung;MHC Class I Genes;Modeling;Molecular;Mouse Strains;Murine leukemia virus;Mus;nano;nanoliposome;Nanotechnology;Nature;neoantigens;Neoplasm Metastasis;next generation sequencing;Oncogenes;particle;peptide I;peptide vaccination;Peptide Vaccines;Peptides;Phagosomes;Phospholipids;Porphyrins;Primary Neoplasm;prophylactic;QS21;recruit;response;Safety;screening;Screening procedure;self assembly;SELL gene;Serum;stem;synthetic peptide;System;T cell infiltration;T cell response;T-Lymphocyte;T-Lymphocyte Epitopes;Techniques;Testing;Therapeutic;therapeutic immunization;therapeutic vaccine;Time;Toll-like receptors;Toxic effect;tumor;Tumor Antigens;Tumor Cell Biology;tumor eradication;Tumor Immunity;tumor microenvironment;Vaccinated;Vaccination;Vaccine Adjuvant;Vaccine Clinical Trial;vaccine efficacy;Viral Antigens

PROJECT_TITLE: A Cobalt Porphyrin Nanoliposome Adjuvant for MHC-I-Restricted Cancer Peptide Vaccines


NIH_SPENDING_CATS: Cancer;Genetics

PHR: CORE A – ADMINISTRATION PROJECT NARRATIVE Core A is responsible for organizing the different components of this Program Project. It provides the infrastructure that organizes Program meetings, oversees Program expenditures, and enriches the scientific environment of the Program. Core A also provides access to a biostatistician to assist investigators within the Program.

PROJECT_TITLE: Core A: Administration


NIH_SPENDING_CATS: Cancer;Climate-Related Exposures and Conditions;Lung;Lung Cancer;Prevention;Rare Diseases;Skin Cancer;Social Determinants of Health;Substance Misuse;Tobacco;Tobacco Smoke and Health

ORG_CITY: PHILADELPHIA

PI_NAMEs: PENNING, TREVOR M (contact)

PROJECT_TERMS: addiction;Address;Affect;Area;Aromatic Polycyclic Hydrocarbons;Asbestos;Cancer Center;Cancer Center Support Grant;Cancer Control;Cancer Etiology;Carcinogen exposure;carcinogenesis;Carcinogenesis Mechanism;Carcinogens;Catchment Area;clinical practice;Collaborations;Communication;Communication Methods;Communities;community based research;Dermatology;Diesel Exhaust;Disease;Education;Educational Activities;effective therapy;Environment;environmental carcinogenesis;Environmental Carcinogens;Environmental Exposure;Environmental Risk Factor;environmental toxicology;Etiology;experience;Exposure to;Faculty;Fostering;Funding;Grant;Human;Image;Immunobiology;improved;Incidence;Institution;Intervention;Lead;Leadership;Light;Link;low nicotine content cigarette;Malignant mesothelioma;Malignant neoplasm of lung;Malignant Neoplasms;medical schools;Medicine;member;Mentors;Mesothelioma;Metabolic;Methods;Mission;National Institute of Drug Abuse;Neurosciences;Nicotine Dependence;novel;Pathway interactions;Pediatrics;Peer Review;Pharmacology;Policies;Population;Population Sciences;Positron-Emission Tomography;Prevention;Process;programs;Psychiatry;Publications;Radiobiology;remediation;Research;Risk;Risk Factors;risk mitigation;Risk Reduction;School Nursing;Schools;Science;Seminal;Skin Cancer;Smoking;symposium;System;Testing;Therapeutic;Tobacco;tobacco advertising;tobacco carcinogenesis;tobacco cessation intervention;tobacco control;Tobacco Dependence;tobacco exposure;tobacco products;Tobacco-Associated Carcinogen;Tobacco-Related Carcinoma;translational therapeutics;treatment trial;Tumor Biology;Ultraviolet Rays;Vision;warning label;Work;working group

PROJECT_TITLE: Tobacco and Environmental Carcinogenesis Program


NIH_SPENDING_CATS: Behavioral and Social Science;Brain Disorders;Clinical Research;Clinical Trials and Supportive Activities;Dissemination and Implementation Research;Drug Abuse (NIDA only);Health Services;Opioid Misuse and Addiction;Opioids;Physical Injury - Accidents and Adverse Effects;Substance Misuse

ORG_CITY: CHICAGO

ORG_NAME: NORTHWESTERN UNIVERSITY AT CHICAGO

ORG_STATE: IL

PHR: PROJECT NARRATIVE  New England is one of the epicenters of the opioid overdose crisis, with five New England states ranking in the top 10 with the highest overdose deaths. This mentored research proposal will evaluate the preliminary effectiveness and implementation of measurement-based care (MBC) as a treatment progress monitoring tool to enhance pharmacological treatment for opioid use disorder in community settings. Results of this rigorous, mixed methods study will advance understanding of MBC’s effectiveness and implementation potential in community opioid treatment programs, setting the stage for future research focused on scaling up MBC to enhance opioid treatment and reduce the impact of the opioid overdose crisis.

PI_NAMEs: SCOTT, KELLI  (contact)

PROGRAM_OFFICER_NAME: MARTIN, LINDSEY ANN

PROJECT_TERMS: Abstinence;Accidents;addiction;Alcohols;Appointment;Area;Behavior Therapy;burden of illness;career;career development;Caring;Censuses;Centers for Disease Control and Prevention (U.S.);Cessation of life;Client;Clinical;cognitive interview;Collection;Communities;community engaged research;community partners;community partnership;community research;community setting;Complement;Computerized Medical Record;Consolidated Framework for Implementation Research;Counseling;Data;Data Collection;Data Reporting;design;Development;Development Plans;Dissemination and Implementation;Documentation;Early identification;Effectiveness;effectiveness outcome;effectiveness/implementation study;effectiveness/implementation trial;Epidemic;Ethnography;evidence base;Evidence based intervention;Evidence based treatment;experience;flexibility;Frequencies;Goals;group counseling;Group Therapy;Guidelines;Health Personnel;Helping to End Addiction Long-term;Hybrids;implementation outcomes;implementation science;improved;Intervention;Interview;Manuals;Measurement;Measures;Mentors;Mentorship;Methods;Modeling;Monitor;multidisciplinary;National Institute of Drug Abuse;New England;Opiate Addiction;Opioid;opioid misuse;opioid overdose;opioid treatment program;opioid use disorder;Outcome;Overdose;overdose death;Patient Self-Report;Patients;Pharmaceutical Preparations;Pharmacological Treatment;Pharmacotherapy;Phase;pilot trial;Policies;Prescription drug overdose;Procedures;Process;Program Development;programs;Protocols documentation;Provider;psychosocial;Public Health;public health emergency;rapid technique;Recommendation;Recording of previous events;Reporting;Research;Research Activity;research and development;Research Personnel;Research Proposals;scale up;Site;Site Visit;Strategic Planning;Structure;substance use treatment;Surveys;Testing;tool;Training;Training Activity;Training Support;United States;United States Department of Veterans Affairs;Universities;Urine;Work

PROJECT_TITLE: Pilot Implementation of Measurement-Based Care in Community Opioid Treatment Programs

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1-HDM-M(04)]